Advertisements


CBRE promotes St. Louis leader, will oversee multiple markets

Jeff Kaiser's promotion follows other personnel change at CBRE's St. Louis office this year......»»

Category: topSource: bizjournalsMar 30th, 2021

China Syndrome? Is Evergrande A Symptom Of Deeper Malaise

China Syndrome? Is Evergrande A Symptom Of Deeper Malaise Authored by Bill Blain via MorningPorridge.com, “If that’s true, we are very close to the China Syndrome ” Evergrande’s imminent default is rocking markets – but few believe the collapse of a Chinese property developer could trigger a global financial crisis. What if Evergrande is just a symptom of a deeper malaise within the Chinese economy and its political/business structures? Maybe there is more at stake than we realise? What if Emperor Xi decides he needs a distraction? Amid this week's market turbulence, and the overnight headlines, Evergrande dominates thinking this morning. The early headlines say the risk is “easing”. Don’t be fooled. S&P are on the wires saying it’s on the brink of default and is unlikely to get govt support. It’s Asia’s largest junk-bond issuer. Anyone for the last few choc-ices then? The market view on the coming Evergrande “event” is mixed. Some analysts are dismissing it as an internal “China event”, others reckon there may be some systemic risk but one Government can easily address. There is some speculation about “lessons” to be learnt… There are even China supporters who reckon its proof of robust China capitalism – the right to fail is a positive! I’ve got a darker perspective. The massive shifts we’ve seen in China’s political/business public persona over the past few years have been variously ascribed: a reaction to Trump’s protectionism, China taking its place as a leading nation, Xi flexing his military muscle, and now a clampdown on divisive wealthy businesses to promote common prosperity. What if Evergrande is just a symptom of something much deeper? That that last 30-years of runaway Chinese growth has resulted in a deepening internal crisis, one that we barely perceive in the west? What if the excesses that have spawned Evergrande and the illusion every Chinese can afford luxury flats and a western standard of living is about to implode? Crashing oriental minor chords! The looming Chinese property debacle will be fascinating, but it many respects will be similar and yet very different to the multiple market unwinds we’ve seen in the west. How it plays out will have all kinds of implications for growth, speculation and how global investors perceive China in the future. Folk are variously describing it as China’s Lehman Brothers, or the next “Minsky Moment” when speculation ends with a sharp jab of reality to the kidneys. I’m thinking back to a story I read a few years ago about the Shanghai Auto-fair pre-pandemic. Evergrande New Electric Vehicles had the largest stand and was showing off 11 different EVs. Not one of these were actually available to buy – they were all models of as-yet unproduced cars. The company was valued at billions and yet never sold a single vehicle. This morning, it’s just another worthless business Evergrande is trying to flog. (See this story on Bloomberg TV: China’s Zombie EV Makers.) The market is asking itself a host of questions about Evergrande’s collapse: How bad will its tsunami of Chinese contagion deluge global markets? When it’s going to happen? What knock-on effects will cascade through markets? Perhaps the most important question is: Who will be exposed “swimming naked” when the Evergrande tide goes out? Who will be left with the biggest losses? As the company is definitely bust, these losses rather depend on just how China’s authorities respond. Step back and think about it a moment – try putting these in context: Fundamentally all business is about identifying a consumer need and filling it. Fundamentally, greedy businessmen tend to get carried away because the political-financial system enables them. Fundamentally, it’s just another burst bubble and who cleans up the mess. In Evergrande’s case a thousand flowers of capitalism with Chinese characteristics grew into an unsustainable business – fundamentally no different from debt-fuelled sub-prime mortgages, or CDOs cubed, in the West. The big difference this time is its China! China has done things… differently. The path China pursued in its recovery and growth since 1980 has not been without… consequences. Thus far we’ve praised China for its spectacular growth and the creation of valuable companies under the red banner of Chinese capitalism. It is going to be “interesting” to see how the subsequent mess is cleared out. Questions about Moral Hazard are going to be shockingly simple – Government has made it abundantly clear that any wrongdoing by company executives will be punished in the harshest possible way. More importantly, Chinese politics and business works on a very different playing field to the west. Forget the rule of law or the T&C’s of Evergrande bonds. It easy to dismiss and characterise the way Chinese business works as institutionalised systemic corruption – but it’s a system Ancient Roman Emperors would recognise as a patron/client relationship. Emperor Xi’s clients and his princelings will continue to benefit from his patronage in return for their support at his court, and will be protected in a meltdown. The system Xi presides over will have little motivation to intervene to protect western investors who find themselves caught in the Evergrande fiasco. Where Xi will have to take notice is outside the rich, wealthy princeling cadre which increasingly owns and runs China. There will be massive implications for wealth/inequality among the Chinese people from a property collapse. With a third of Chinese GDP dependent on the property sector, (and about 4 million jobs at Evergrande), the collapse of one of the biggest players, and the likelihood others will follow is much more than just a systemic risk. Property is a key metric in the aspirations to wealth of the rising Chinese middle classes. The same smaller Chinese investors and savers will likely prove the largest losers from the property investment schemes they were sucked into. These real losses will rise if hidden bank exposures trigger a domestic banking crisis – which apparently isn’t likely (meaning it is..). There are reports of investor protests in key China cities – putting pressure on the govt to act to mitigate personal losses. Xi’s clampdown on big tech is painted as the Party’s programme to engineer a more socially-equal economy. He has pinned the blame for rising inequality on “corrupt” business practices and has his cadre’s waving books on Xi thought, mouthing slogans about “common prosperity” and “frugality”. These are going to look increasingly hollow if the middle classes bear the coming Evergrande pain, and the Party Princelings continue to prosper. The really big risk in China is not that Evergrande is going to default – it’s much bigger. If the Party is seen to fail in its promise to deliver wealth, jobs and prosperity for the masses – then that is very serious. China’s host of failed EV companies, an economy still reliant on exporting other nations tech, and a massively overvalued property sector (that the masses still equate with prosperity) all suggest a much less solid economy than the Party promotes. If the illusion of a strong economy is unravelling – who knows what happens next, but in Ancient Rome the answer would be simple… Blame someone else, and invade.. This could get very “interesting…” and not in a good way. Tyler Durden Wed, 09/22/2021 - 08:45.....»»

Category: blogSource: zerohedgeSep 22nd, 2021

Micron CEO: Very excited about strength in multiple end markets

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 1st, 2021

Gensler promotes Dallas leader to regional role

Gensler announced Tuesday that Cindy Simpson has been promoted to the role of co-regional managing principal for Gensler's South Central Region, in which she will work alongside Judy Pesek. Simpson and Pesek will oversee Gensler's offices in Dalla.....»»

Category: topSource: bizjournalsJan 8th, 2020

DBJ publisher promoted, will oversee additional Business Journals

Tracy Merzi, market president and publisher of the Dallas Business Journal, will be expanding her geographic oversight within parent company American City Business Journals (ACBJ) to include multiple other markets along with Dallas. The new posit.....»»

Category: topSource: bizjournalsAug 22nd, 2018

The Harsh Truth Behind Europe"s Energy Crisis

The Harsh Truth Behind Europe's Energy Crisis Authored by By Cyril Widdershoven via OilPrice.com, Europe’s energy crunch is continuing, as gas storage volumes have shrunk to 10-year lows. A possible harsh winter could lead to severe energy shortages and possible shutdowns of large parts of the economy. While the main discussion is currently focused on the potential role of Russia in the energy crisis, a new narrative could soon make the headlines. In a surprise move, the Dutch government has indicated that in a severe supply crunch situation, the Groningen gas field, Europe’s largest onshore gas field, could partially and temporarily be reopened. It seems that the term Dutch Disease could get a new meaning, from being the paradox of a rentier state suffering from plentiful resources to a show of Europe’s lack of realism when it comes to energy transition risks and current market powers.   Dutch Minister Stef Blok has indicated that he is considering the potential reopening of the Groningen field, in particular five wells, especially the one at Slochteren, as indicated by Johan Attema, director of the Nederlandse Aardolie Maatschappij (NAM), the operator of the Groningen field. The reopening of the field, even in the case of an emergency or an energy crisis, is politically controversial. Until recently, the plan was that Groningen would be closed completely by 2023, ending the large-scale gas production and export by the Netherlands with a bang. The Dutch media is speculating that minister Blok will be asking for a possible reopening of the Groningen field, a decision that must be made before October 1. If the Minister decides to change the current shutdown plans, the whole Groningen debacle, as some see it, will be prolonged. It is clear, looking at the current deplorable situation of the European energy sector, that Groningen is still needed. The ongoing energy crunch could have grave consequences for the economies and wellbeing of EU member states, changing the narratives in Brussels and the respective European capitals.   The lack of supply of natural gas by Russia (or the political will to supply more), the difficulty of ramping up Norwegian gas or other gas imports quickly, is jeopardizing Europe’s energy situation. At the same time, a possible shutdown of several electricity-intensive industries in Europe, such as fertilizers, chemicals, and steel/aluminum production is on the table. Political leaders will have to face the direct implications of higher energy bills or possible energy deficits for consumers and the industry. Both could lead to protests or political landslides during upcoming elections. Threats of an energy crisis are being discussed widely, but no real solutions except lower taxes are available. Due to higher energy costs, a possible record price level of $100 MMBtu or $250 per barrel of crude oil equivalent is very bad news for politicians, especially in the Netherlands, Germany, France, and the UK.   It remains unclear, however, whether European politicians are aware of the role that their own policies have played in creating this crisis. Even with the partial restart of the Groningen field, which could relieve some of the pain in Western Europe, there is a larger problem that must be addressed.  By opening up the gas market for liberalization, without giving the necessary tools to parties, and pushing for a spot market, instability was introduced into the system. Geopolitical powers are still at play, while utilities and European suppliers have seen little support from their governments. At the same time, when oil price-indexed long-term contracts with Russia were thrown out of the window, many did not understand that this could mean handing over full market powers to NOCs, such as Gazprom. Putin has been celebrating, knowing that he has been handed the key to European markets, with the option of manipulating fundamentals and prices at the same time. In the meantime, Europe has failed to sufficiently diversify supply.   European leaders desperately need to reconsider their position towards Russian gas supplies and the future role of NordStream 2, which is still being threatened by US sanctions and Eastern European opposition. It seems that Russia’s leader Vladimir Putin, however, is holding all the cards when it comes to natural gas in Europe. Without substantially more natural gas supply to Europe, consumers and industry may well be facing a winter of discontent. Europe’s gas supply diversification strategy has been a failure, not only due to EU tactics and regulations but also because of the ongoing one-sided emphasis on a rapid energy transition, hydrocarbon divestment, and full-scale investments in renewables, without realizing that the backbone of the European economic system is still hydrocarbon fueled.   The current situation shows one main fact of life, the success of the energy transition is not based on a one-sided approach. By relying too much on renewables, the market became destabilized, but politicians and others didn’t want to admit it. Destabilization could and should be prevented, by acknowledging the fact that for the foreseeable future hydrocarbons, including coal, will be playing a significant role in the European energy market.At the same time, European politicians also should acknowledge that without hydrocarbons, not only does energy supply become threatened, but the hydrocarbon economy suffers. It is not yet fully understood by most, but without hydrocarbons, especially natural gas and oil, food and other primary sectors will be hit hard. The first shutdowns of fertilizer and steel companies have already been reported.   Brussels, London, Berlin, and even The Hague, should start to change their approach to energy and the economy of the future. Politicians should start to listen to market analysts that have been warning of a disruption in energy markets. The European long-term energy strategy should acknowledge the position of hydrocarbons as a backbone while investing in renewable options at the same time. Investments in storage, diversified supply, and domestic production are crucial.  Without these, supply giants such as Putin’s Russia are holding all the cards.   Tyler Durden Mon, 09/27/2021 - 02:00.....»»

Category: dealsSource: nyt31 min. ago

"Damn You To Hell, You Will Not Destroy America" - Here Is The "Spartacus COVID Letter" That"s Gone Viral

"Damn You To Hell, You Will Not Destroy America" - Here Is The 'Spartacus COVID Letter' That's Gone Viral Via The Automatic Earth blog, This is an anonymously posted document by someone who calls themselves Spartacus. Because it’s anonymous, I can’t contact them to ask for permission to publish. So I hesitated for a while, but it’s simply the best document I’ve seen on Covid, vaccines, etc. Whoever Spartacus is, they have a very elaborate knowledge in “the field”. If you want to know a lot more about the no. 1 issue in the world today, read it. And don’t worry if you don’t understand every single word, neither do I. But I learned a lot. The original PDF doc is here: Covid19 – The Spartacus Letter Hello, My name is Spartacus, and I’ve had enough. We have been forced to watch America and the Free World spin into inexorable decline due to a biowarfare attack. We, along with countless others, have been victimized and gaslit by propaganda and psychological warfare operations being conducted by an unelected, unaccountable Elite against the American people and our allies. Our mental and physical health have suffered immensely over the course of the past year and a half. We have felt the sting of isolation, lockdown, masking, quarantines, and other completely nonsensical acts of healthcare theater that have done absolutely nothing to protect the health or wellbeing of the public from the ongoing COVID-19 pandemic. Now, we are watching the medical establishment inject literal poison into millions of our fellow Americans without so much as a fight. We have been told that we will be fired and denied our livelihoods if we refuse to vaccinate. This was the last straw. We have spent thousands of hours analyzing leaked footage from Wuhan, scientific papers from primary sources, as well as the paper trails left by the medical establishment. What we have discovered would shock anyone to their core. First, we will summarize our findings, and then, we will explain them in detail. References will be placed at the end. Summary: COVID-19 is a blood and blood vessel disease. SARS-CoV-2 infects the lining of human blood vessels, causing them to leak into the lungs. Current treatment protocols (e.g. invasive ventilation) are actively harmful to patients, accelerating oxidative stress and causing severe VILI (ventilator-induced lung injuries). The continued use of ventilators in the absence of any proven medical benefit constitutes mass murder. Existing countermeasures are inadequate to slow the spread of what is an aerosolized and potentially wastewater-borne virus, and constitute a form of medical theater. Various non-vaccine interventions have been suppressed by both the media and the medical establishment in favor of vaccines and expensive patented drugs. The authorities have denied the usefulness of natural immunity against COVID-19, despite the fact that natural immunity confers protection against all of the virus’s proteins, and not just one. Vaccines will do more harm than good. The antigen that these vaccines are based on, SARS-CoV- 2 Spike, is a toxic protein. SARS-CoV-2 may have ADE, or antibody-dependent enhancement; current antibodies may not neutralize future strains, but instead help them infect immune cells. Also, vaccinating during a pandemic with a leaky vaccine removes the evolutionary pressure for a virus to become less lethal. There is a vast and appalling criminal conspiracy that directly links both Anthony Fauci and Moderna to the Wuhan Institute of Virology. COVID-19 vaccine researchers are directly linked to scientists involved in brain-computer interface (“neural lace”) tech, one of whom was indicted for taking grant money from China. Independent researchers have discovered mysterious nanoparticles inside the vaccines that are not supposed to be present. The entire pandemic is being used as an excuse for a vast political and economic transformation of Western society that will enrich the already rich and turn the rest of us into serfs and untouchables. COVID-19 Pathophysiology and Treatments: COVID-19 is not a viral pneumonia. It is a viral vascular endotheliitis and attacks the lining of blood vessels, particularly the small pulmonary alveolar capillaries, leading to endothelial cell activation and sloughing, coagulopathy, sepsis, pulmonary edema, and ARDS-like symptoms. This is a disease of the blood and blood vessels. The circulatory system. Any pneumonia that it causes is secondary to that. In severe cases, this leads to sepsis, blood clots, and multiple organ failure, including hypoxic and inflammatory damage to various vital organs, such as the brain, heart, liver, pancreas, kidneys, and intestines. Some of the most common laboratory findings in COVID-19 are elevated D-dimer, elevated prothrombin time, elevated C-reactive protein, neutrophilia, lymphopenia, hypocalcemia, and hyperferritinemia, essentially matching a profile of coagulopathy and immune system hyperactivation/immune cell exhaustion. COVID-19 can present as almost anything, due to the wide tropism of SARS-CoV-2 for various tissues in the body’s vital organs. While its most common initial presentation is respiratory illness and flu-like symptoms, it can present as brain inflammation, gastrointestinal disease, or even heart attack or pulmonary embolism. COVID-19 is more severe in those with specific comorbidities, such as obesity, diabetes, and hypertension. This is because these conditions involve endothelial dysfunction, which renders the circulatory system more susceptible to infection and injury by this particular virus. The vast majority of COVID-19 cases are mild and do not cause significant disease. In known cases, there is something known as the 80/20 rule, where 80% of cases are mild and 20% are severe or critical. However, this ratio is only correct for known cases, not all infections. The number of actual infections is much, much higher. Consequently, the mortality and morbidity rate is lower. However, COVID-19 spreads very quickly, meaning that there are a significant number of severely-ill and critically-ill patients appearing in a short time frame. In those who have critical COVID-19-induced sepsis, hypoxia, coagulopathy, and ARDS, the most common treatments are intubation, injected corticosteroids, and blood thinners. This is not the correct treatment for COVID-19. In severe hypoxia, cellular metabolic shifts cause ATP to break down into hypoxanthine, which, upon the reintroduction of oxygen, causes xanthine oxidase to produce tons of highly damaging radicals that attack tissue. This is called ischemia-reperfusion injury, and it’s why the majority of people who go on a ventilator are dying. In the mitochondria, succinate buildup due to sepsis does the same exact thing; when oxygen is reintroduced, it makes superoxide radicals. Make no mistake, intubation will kill people who have COVID-19. The end-stage of COVID-19 is severe lipid peroxidation, where fats in the body start to “rust” due to damage by oxidative stress. This drives autoimmunity. Oxidized lipids appear as foreign objects to the immune system, which recognizes and forms antibodies against OSEs, or oxidation-specific epitopes. Also, oxidized lipids feed directly into pattern recognition receptors, triggering even more inflammation and summoning even more cells of the innate immune system that release even more destructive enzymes. This is similar to the pathophysiology of Lupus. COVID-19’s pathology is dominated by extreme oxidative stress and neutrophil respiratory burst, to the point where hemoglobin becomes incapable of carrying oxygen due to heme iron being stripped out of heme by hypochlorous acid. No amount of supplemental oxygen can oxygenate blood that chemically refuses to bind O2. The breakdown of the pathology is as follows: SARS-CoV-2 Spike binds to ACE2. Angiotensin Converting Enzyme 2 is an enzyme that is part of the renin-angiotensin-aldosterone system, or RAAS. The RAAS is a hormone control system that moderates fluid volume in the body and in the bloodstream (i.e. osmolarity) by controlling salt retention and excretion. This protein, ACE2, is ubiquitous in every part of the body that interfaces with the circulatory system, particularly in vascular endothelial cells and pericytes, brain astrocytes, renal tubules and podocytes, pancreatic islet cells, bile duct and intestinal epithelial cells, and the seminiferous ducts of the testis, all of which SARS-CoV-2 can infect, not just the lungs. SARS-CoV-2 infects a cell as follows: SARS-CoV-2 Spike undergoes a conformational change where the S1 trimers flip up and extend, locking onto ACE2 bound to the surface of a cell. TMPRSS2, or transmembrane protease serine 2, comes along and cuts off the heads of the Spike, exposing the S2 stalk-shaped subunit inside. The remainder of the Spike undergoes a conformational change that causes it to unfold like an extension ladder, embedding itself in the cell membrane. Then, it folds back upon itself, pulling the viral membrane and the cell membrane together. The two membranes fuse, with the virus’s proteins migrating out onto the surface of the cell. The SARS-CoV-2 nucleocapsid enters the cell, disgorging its genetic material and beginning the viral replication process, hijacking the cell’s own structures to produce more virus. SARS-CoV-2 Spike proteins embedded in a cell can actually cause human cells to fuse together, forming syncytia/MGCs (multinuclear giant cells). They also have other pathogenic, harmful effects. SARS-CoV- 2’s viroporins, such as its Envelope protein, act as calcium ion channels, introducing calcium into infected cells. The virus suppresses the natural interferon response, resulting in delayed inflammation. SARS-CoV-2 N protein can also directly activate the NLRP3 inflammasome. Also, it suppresses the Nrf2 antioxidant pathway. The suppression of ACE2 by binding with Spike causes a buildup of bradykinin that would otherwise be broken down by ACE2. This constant calcium influx into the cells results in (or is accompanied by) noticeable hypocalcemia, or low blood calcium, especially in people with Vitamin D deficiencies and pre-existing endothelial dysfunction. Bradykinin upregulates cAMP, cGMP, COX, and Phospholipase C activity. This results in prostaglandin release and vastly increased intracellular calcium signaling, which promotes highly aggressive ROS release and ATP depletion. NADPH oxidase releases superoxide into the extracellular space. Superoxide radicals react with nitric oxide to form peroxynitrite. Peroxynitrite reacts with the tetrahydrobiopterin cofactor needed by endothelial nitric oxide synthase, destroying it and “uncoupling” the enzymes, causing nitric oxide synthase to synthesize more superoxide instead. This proceeds in a positive feedback loop until nitric oxide bioavailability in the circulatory system is depleted. Dissolved nitric oxide gas produced constantly by eNOS serves many important functions, but it is also antiviral against SARS-like coronaviruses, preventing the palmitoylation of the viral Spike protein and making it harder for it to bind to host receptors. The loss of NO allows the virus to begin replicating with impunity in the body. Those with endothelial dysfunction (i.e. hypertension, diabetes, obesity, old age, African-American race) have redox equilibrium issues to begin with, giving the virus an advantage. Due to the extreme cytokine release triggered by these processes, the body summons a great deal of neutrophils and monocyte-derived alveolar macrophages to the lungs. Cells of the innate immune system are the first-line defenders against pathogens. They work by engulfing invaders and trying to attack them with enzymes that produce powerful oxidants, like SOD and MPO. Superoxide dismutase takes superoxide and makes hydrogen peroxide, and myeloperoxidase takes hydrogen peroxide and chlorine ions and makes hypochlorous acid, which is many, many times more reactive than sodium hypochlorite bleach. Neutrophils have a nasty trick. They can also eject these enzymes into the extracellular space, where they will continuously spit out peroxide and bleach into the bloodstream. This is called neutrophil extracellular trap formation, or, when it becomes pathogenic and counterproductive, NETosis. In severe and critical COVID-19, there is actually rather severe NETosis. Hypochlorous acid building up in the bloodstream begins to bleach the iron out of heme and compete for O2 binding sites. Red blood cells lose the ability to transport oxygen, causing the sufferer to turn blue in the face. Unliganded iron, hydrogen peroxide, and superoxide in the bloodstream undergo the Haber- Weiss and Fenton reactions, producing extremely reactive hydroxyl radicals that violently strip electrons from surrounding fats and DNA, oxidizing them severely. This condition is not unknown to medical science. The actual name for all of this is acute sepsis. We know this is happening in COVID-19 because people who have died of the disease have noticeable ferroptosis signatures in their tissues, as well as various other oxidative stress markers such as nitrotyrosine, 4-HNE, and malondialdehyde. When you intubate someone with this condition, you are setting off a free radical bomb by supplying the cells with O2. It’s a catch-22, because we need oxygen to make Adenosine Triphosphate (that is, to live), but O2 is also the precursor of all these damaging radicals that lead to lipid peroxidation. The correct treatment for severe COVID-19 related sepsis is non-invasive ventilation, steroids, and antioxidant infusions. Most of the drugs repurposed for COVID-19 that show any benefit whatsoever in rescuing critically-ill COVID-19 patients are antioxidants. N-acetylcysteine, melatonin, fluvoxamine, budesonide, famotidine, cimetidine, and ranitidine are all antioxidants. Indomethacin prevents iron- driven oxidation of arachidonic acid to isoprostanes. There are powerful antioxidants such as apocynin that have not even been tested on COVID-19 patients yet which could defang neutrophils, prevent lipid peroxidation, restore endothelial health, and restore oxygenation to the tissues. Scientists who know anything about pulmonary neutrophilia, ARDS, and redox biology have known or surmised much of this since March 2020. In April 2020, Swiss scientists confirmed that COVID-19 was a vascular endotheliitis. By late 2020, experts had already concluded that COVID-19 causes a form of viral sepsis. They also know that sepsis can be effectively treated with antioxidants. None of this information is particularly new, and yet, for the most part, it has not been acted upon. Doctors continue to use damaging intubation techniques with high PEEP settings despite high lung compliance and poor oxygenation, killing an untold number of critically ill patients with medical malpractice. Because of the way they are constructed, Randomized Control Trials will never show any benefit for any antiviral against COVID-19. Not Remdesivir, not Kaletra, not HCQ, and not Ivermectin. The reason for this is simple; for the patients that they have recruited for these studies, such as Oxford’s ludicrous RECOVERY study, the intervention is too late to have any positive effect. The clinical course of COVID-19 is such that by the time most people seek medical attention for hypoxia, their viral load has already tapered off to almost nothing. If someone is about 10 days post-exposure and has already been symptomatic for five days, there is hardly any virus left in their bodies, only cellular damage and derangement that has initiated a hyperinflammatory response. It is from this group that the clinical trials for antivirals have recruited, pretty much exclusively. In these trials, they give antivirals to severely ill patients who have no virus in their bodies, only a delayed hyperinflammatory response, and then absurdly claim that antivirals have no utility in treating or preventing COVID-19. These clinical trials do not recruit people who are pre-symptomatic. They do not test pre-exposure or post-exposure prophylaxis. This is like using a defibrillator to shock only flatline, and then absurdly claiming that defibrillators have no medical utility whatsoever when the patients refuse to rise from the dead. The intervention is too late. These trials for antivirals show systematic, egregious selection bias. They are providing a treatment that is futile to the specific cohort they are enrolling. India went against the instructions of the WHO and mandated the prophylactic usage of Ivermectin. They have almost completely eradicated COVID-19. The Indian Bar Association of Mumbai has brought criminal charges against WHO Chief Scientist Dr. Soumya Swaminathan for recommending against the use of Ivermectin. Ivermectin is not “horse dewormer”. Yes, it is sold in veterinary paste form as a dewormer for animals. It has also been available in pill form for humans for decades, as an antiparasitic drug. The media have disingenuously claimed that because Ivermectin is an antiparasitic drug, it has no utility as an antivirus. This is incorrect. Ivermectin has utility as an antiviral. It blocks importin, preventing nuclear import, effectively inhibiting viral access to cell nuclei. Many drugs currently on the market have multiple modes of action. Ivermectin is one such drug. It is both antiparasitic and antiviral. In Bangladesh, Ivermectin costs $1.80 for an entire 5-day course. Remdesivir, which is toxic to the liver, costs $3,120 for a 5-day course of the drug. Billions of dollars of utterly useless Remdesivir were sold to our governments on the taxpayer’s dime, and it ended up being totally useless for treating hyperinflammatory COVID-19. The media has hardly even covered this at all. The opposition to the use of generic Ivermectin is not based in science. It is purely financially and politically-motivated. An effective non-vaccine intervention would jeopardize the rushed FDA approval of patented vaccines and medicines for which the pharmaceutical industry stands to rake in billions upon billions of dollars in sales on an ongoing basis. The majority of the public are scientifically illiterate and cannot grasp what any of this even means, thanks to a pathetic educational system that has miseducated them. You would be lucky to find 1 in 100 people who have even the faintest clue what any of this actually means. COVID-19 Transmission: COVID-19 is airborne. The WHO carried water for China by claiming that the virus was only droplet- borne. Our own CDC absurdly claimed that it was mostly transmitted by fomite-to-face contact, which, given its rapid spread from Wuhan to the rest of the world, would have been physically impossible. The ridiculous belief in fomite-to-face being a primary mode of transmission led to the use of surface disinfection protocols that wasted time, energy, productivity, and disinfectant. The 6-foot guidelines are absolutely useless. The minimum safe distance to protect oneself from an aerosolized virus is to be 15+ feet away from an infected person, no closer. Realistically, no public transit is safe. Surgical masks do not protect you from aerosols. The virus is too small and the filter media has too large of gaps to filter it out. They may catch respiratory droplets and keep the virus from being expelled by someone who is sick, but they do not filter a cloud of infectious aerosols if someone were to walk into said cloud. The minimum level of protection against this virus is quite literally a P100 respirator, a PAPR/CAPR, or a 40mm NATO CBRN respirator, ideally paired with a full-body tyvek or tychem suit, gloves, and booties, with all the holes and gaps taped. Live SARS-CoV-2 may potentially be detected in sewage outflows, and there may be oral-fecal transmission. During the SARS outbreak in 2003, in the Amoy Gardens incident, hundreds of people were infected by aerosolized fecal matter rising from floor drains in their apartments. COVID-19 Vaccine Dangers: The vaccines for COVID-19 are not sterilizing and do not prevent infection or transmission. They are “leaky” vaccines. This means they remove the evolutionary pressure on the virus to become less lethal. It also means that the vaccinated are perfect carriers. In other words, those who are vaccinated are a threat to the unvaccinated, not the other way around. All of the COVID-19 vaccines currently in use have undergone minimal testing, with highly accelerated clinical trials. Though they appear to limit severe illness, the long-term safety profile of these vaccines remains unknown. Some of these so-called “vaccines” utilize an untested new technology that has never been used in vaccines before. Traditional vaccines use weakened or killed virus to stimulate an immune response. The Moderna and Pfizer-BioNTech vaccines do not. They are purported to consist of an intramuscular shot containing a suspension of lipid nanoparticles filled with messenger RNA. The way they generate an immune response is by fusing with cells in a vaccine recipient’s shoulder, undergoing endocytosis, releasing their mRNA cargo into those cells, and then utilizing the ribosomes in those cells to synthesize modified SARS-CoV-2 Spike proteins in-situ. These modified Spike proteins then migrate to the surface of the cell, where they are anchored in place by a transmembrane domain. The adaptive immune system detects the non-human viral protein being expressed by these cells, and then forms antibodies against that protein. This is purported to confer protection against the virus, by training the adaptive immune system to recognize and produce antibodies against the Spike on the actual virus. The J&J and AstraZeneca vaccines do something similar, but use an adenovirus vector for genetic material delivery instead of a lipid nanoparticle. These vaccines were produced or validated with the aid of fetal cell lines HEK-293 and PER.C6, which people with certain religious convictions may object strongly to. SARS-CoV-2 Spike is a highly pathogenic protein on its own. It is impossible to overstate the danger presented by introducing this protein into the human body. It is claimed by vaccine manufacturers that the vaccine remains in cells in the shoulder, and that SARS- CoV-2 Spike produced and expressed by these cells from the vaccine’s genetic material is harmless and inert, thanks to the insertion of prolines in the Spike sequence to stabilize it in the prefusion conformation, preventing the Spike from becoming active and fusing with other cells. However, a pharmacokinetic study from Japan showed that the lipid nanoparticles and mRNA from the Pfizer vaccine did not stay in the shoulder, and in fact bioaccumulated in many different organs, including the reproductive organs and adrenal glands, meaning that modified Spike is being expressed quite literally all over the place. These lipid nanoparticles may trigger anaphylaxis in an unlucky few, but far more concerning is the unregulated expression of Spike in various somatic cell lines far from the injection site and the unknown consequences of that. Messenger RNA is normally consumed right after it is produced in the body, being translated into a protein by a ribosome. COVID-19 vaccine mRNA is produced outside the body, long before a ribosome translates it. In the meantime, it could accumulate damage if inadequately preserved. When a ribosome attempts to translate a damaged strand of mRNA, it can become stalled. When this happens, the ribosome becomes useless for translating proteins because it now has a piece of mRNA stuck in it, like a lace card in an old punch card reader. The whole thing has to be cleaned up and new ribosomes synthesized to replace it. In cells with low ribosome turnover, like nerve cells, this can lead to reduced protein synthesis, cytopathic effects, and neuropathies. Certain proteins, including SARS-CoV-2 Spike, have proteolytic cleavage sites that are basically like little dotted lines that say “cut here”, which attract a living organism’s own proteases (essentially, molecular scissors) to cut them. There is a possibility that S1 may be proteolytically cleaved from S2, causing active S1 to float away into the bloodstream while leaving the S2 “stalk” embedded in the membrane of the cell that expressed the protein. SARS-CoV-2 Spike has a Superantigenic region (SAg), which may promote extreme inflammation. Anti-Spike antibodies were found in one study to function as autoantibodies and attack the body’s own cells. Those who have been immunized with COVID-19 vaccines have developed blood clots, myocarditis, Guillain-Barre Syndrome, Bell’s Palsy, and multiple sclerosis flares, indicating that the vaccine promotes autoimmune reactions against healthy tissue. SARS-CoV-2 Spike does not only bind to ACE2. It was suspected to have regions that bind to basigin, integrins, neuropilin-1, and bacterial lipopolysaccharides as well. SARS-CoV-2 Spike, on its own, can potentially bind any of these things and act as a ligand for them, triggering unspecified and likely highly inflammatory cellular activity. SARS-CoV-2 Spike contains an unusual PRRA insert that forms a furin cleavage site. Furin is a ubiquitous human protease, making this an ideal property for the Spike to have, giving it a high degree of cell tropism. No wild-type SARS-like coronaviruses related to SARS-CoV-2 possess this feature, making it highly suspicious, and perhaps a sign of human tampering. SARS-CoV-2 Spike has a prion-like domain that enhances its infectiousness. The Spike S1 RBD may bind to heparin-binding proteins and promote amyloid aggregation. In humans, this could lead to Parkinson’s, Lewy Body Dementia, premature Alzheimer’s, or various other neurodegenerative diseases. This is very concerning because SARS-CoV-2 S1 is capable of injuring and penetrating the blood-brain barrier and entering the brain. It is also capable of increasing the permeability of the blood-brain barrier to other molecules. SARS-CoV-2, like other betacoronaviruses, may have Dengue-like ADE, or antibody-dependent enhancement of disease. For those who aren’t aware, some viruses, including betacoronaviruses, have a feature called ADE. There is also something called Original Antigenic Sin, which is the observation that the body prefers to produce antibodies based on previously-encountered strains of a virus over newly- encountered ones. In ADE, antibodies from a previous infection become non-neutralizing due to mutations in the virus’s proteins. These non-neutralizing antibodies then act as trojan horses, allowing live, active virus to be pulled into macrophages through their Fc receptor pathways, allowing the virus to infect immune cells that it would not have been able to infect before. This has been known to happen with Dengue Fever; when someone gets sick with Dengue, recovers, and then contracts a different strain, they can get very, very ill. If someone is vaccinated with mRNA based on the Spike from the initial Wuhan strain of SARS-CoV-2, and then they become infected with a future, mutated strain of the virus, they may become severely ill. In other words, it is possible for vaccines to sensitize someone to disease. There is a precedent for this in recent history. Sanofi’s Dengvaxia vaccine for Dengue failed because it caused immune sensitization in people whose immune systems were Dengue-naive. In mice immunized against SARS-CoV and challenged with the virus, a close relative of SARS-CoV-2, they developed immune sensitization, Th2 immunopathology, and eosinophil infiltration in their lungs. We have been told that SARS-CoV-2 mRNA vaccines cannot be integrated into the human genome, because messenger RNA cannot be turned back into DNA. This is false. There are elements in human cells called LINE-1 retrotransposons, which can indeed integrate mRNA into a human genome by endogenous reverse transcription. Because the mRNA used in the vaccines is stabilized, it hangs around in cells longer, increasing the chances for this to happen. If the gene for SARS-CoV-2 Spike is integrated into a portion of the genome that is not silent and actually expresses a protein, it is possible that people who take this vaccine may continuously express SARS-CoV-2 Spike from their somatic cells for the rest of their lives. By inoculating people with a vaccine that causes their bodies to produce Spike in-situ, they are being inoculated with a pathogenic protein. A toxin that may cause long-term inflammation, heart problems, and a raised risk of cancers. In the long-term, it may also potentially lead to premature neurodegenerative disease. Absolutely nobody should be compelled to take this vaccine under any circumstances, and in actual fact, the vaccination campaign must be stopped immediately. COVID-19 Criminal Conspiracy: The vaccine and the virus were made by the same people. In 2014, there was a moratorium on SARS gain-of-function research that lasted until 2017. This research was not halted. Instead, it was outsourced, with the federal grants being laundered through NGOs. Ralph Baric is a virologist and SARS expert at UNC Chapel Hill in North Carolina. This is who Anthony Fauci was referring to when he insisted, before Congress, that if any gain-of-function research was being conducted, it was being conducted in North Carolina. This was a lie. Anthony Fauci lied before Congress. A felony. Ralph Baric and Shi Zhengli are colleagues and have co-written papers together. Ralph Baric mentored Shi Zhengli in his gain-of-function manipulation techniques, particularly serial passage, which results in a virus that appears as if it originated naturally. In other words, deniable bioweapons. Serial passage in humanized hACE2 mice may have produced something like SARS-CoV-2. The funding for the gain-of-function research being conducted at the Wuhan Institute of Virology came from Peter Daszak. Peter Daszak runs an NGO called EcoHealth Alliance. EcoHealth Alliance received millions of dollars in grant money from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (that is, Anthony Fauci), the Defense Threat Reduction Agency (part of the US Department of Defense), and the United States Agency for International Development. NIH/NIAID contributed a few million dollars, and DTRA and USAID each contributed tens of millions of dollars towards this research. Altogether, it was over a hundred million dollars. EcoHealth Alliance subcontracted these grants to the Wuhan Institute of Virology, a lab in China with a very questionable safety record and poorly trained staff, so that they could conduct gain-of-function research, not in their fancy P4 lab, but in a level-2 lab where technicians wore nothing more sophisticated than perhaps a hairnet, latex gloves, and a surgical mask, instead of the bubble suits used when working with dangerous viruses. Chinese scientists in Wuhan reported being routinely bitten and urinated on by laboratory animals. Why anyone would outsource this dangerous and delicate work to the People’s Republic of China, a country infamous for industrial accidents and massive explosions that have claimed hundreds of lives, is completely beyond me, unless the aim was to start a pandemic on purpose. In November of 2019, three technicians at the Wuhan Institute of Virology developed symptoms consistent with a flu-like illness. Anthony Fauci, Peter Daszak, and Ralph Baric knew at once what had happened, because back channels exist between this laboratory and our scientists and officials. December 12th, 2019, Ralph Baric signed a Material Transfer Agreement (essentially, an NDA) to receive Coronavirus mRNA vaccine-related materials co-owned by Moderna and NIH. It wasn’t until a whole month later, on January 11th, 2020, that China allegedly sent us the sequence to what would become known as SARS-CoV-2. Moderna claims, rather absurdly, that they developed a working vaccine from this sequence in under 48 hours. Stephane Bancel, the current CEO of Moderna, was formerly the CEO of bioMerieux, a French multinational corporation specializing in medical diagnostic tech, founded by one Alain Merieux. Alain Merieux was one of the individuals who was instrumental in the construction of the Wuhan Institute of Virology’s P4 lab. The sequence given as the closest relative to SARS-CoV-2, RaTG13, is not a real virus. It is a forgery. It was made by entering a gene sequence by hand into a database, to create a cover story for the existence of SARS-CoV-2, which is very likely a gain-of-function chimera produced at the Wuhan Institute of Virology and was either leaked by accident or intentionally released. The animal reservoir of SARS-CoV-2 has never been found. This is not a conspiracy “theory”. It is an actual criminal conspiracy, in which people connected to the development of Moderna’s mRNA-1273 are directly connected to the Wuhan Institute of Virology and their gain-of-function research by very few degrees of separation, if any. The paper trail is well- established. The lab-leak theory has been suppressed because pulling that thread leads one to inevitably conclude that there is enough circumstantial evidence to link Moderna, the NIH, the WIV, and both the vaccine and the virus’s creation together. In a sane country, this would have immediately led to the world’s biggest RICO and mass murder case. Anthony Fauci, Peter Daszak, Ralph Baric, Shi Zhengli, and Stephane Bancel, and their accomplices, would have been indicted and prosecuted to the fullest extent of the law. Instead, billions of our tax dollars were awarded to the perpetrators. The FBI raided Allure Medical in Shelby Township north of Detroit for billing insurance for “fraudulent COVID-19 cures”. The treatment they were using? Intravenous Vitamin C. An antioxidant. Which, as described above, is an entirely valid treatment for COVID-19-induced sepsis, and indeed, is now part of the MATH+ protocol advanced by Dr. Paul E. Marik. The FDA banned ranitidine (Zantac) due to supposed NDMA (N-nitrosodimethylamine) contamination. Ranitidine is not only an H2 blocker used as antacid, but also has a powerful antioxidant effect, scavenging hydroxyl radicals. This gives it utility in treating COVID-19. The FDA also attempted to take N-acetylcysteine, a harmless amino acid supplement and antioxidant, off the shelves, compelling Amazon to remove it from their online storefront. This leaves us with a chilling question: did the FDA knowingly suppress antioxidants useful for treating COVID-19 sepsis as part of a criminal conspiracy against the American public? The establishment is cooperating with, and facilitating, the worst criminals in human history, and are actively suppressing non-vaccine treatments and therapies in order to compel us to inject these criminals’ products into our bodies. This is absolutely unacceptable. COVID-19 Vaccine Development and Links to Transhumanism: This section deals with some more speculative aspects of the pandemic and the medical and scientific establishment’s reaction to it, as well as the disturbing links between scientists involved in vaccine research and scientists whose work involved merging nanotechnology with living cells. On June 9th, 2020, Charles Lieber, a Harvard nanotechnology researcher with decades of experience, was indicted by the DOJ for fraud. Charles Lieber received millions of dollars in grant money from the US Department of Defense, specifically the military think tanks DARPA, AFOSR, and ONR, as well as NIH and MITRE. His specialty is the use of silicon nanowires in lieu of patch clamp electrodes to monitor and modulate intracellular activity, something he has been working on at Harvard for the past twenty years. He was claimed to have been working on silicon nanowire batteries in China, but none of his colleagues can recall him ever having worked on battery technology in his life; all of his research deals with bionanotechnology, or the blending of nanotech with living cells. The indictment was over his collaboration with the Wuhan University of Technology. He had double- dipped, against the terms of his DOD grants, and taken money from the PRC’s Thousand Talents plan, a program which the Chinese government uses to bribe Western scientists into sharing proprietary R&D information that can be exploited by the PLA for strategic advantage. Charles Lieber’s own papers describe the use of silicon nanowires for brain-computer interfaces, or “neural lace” technology. His papers describe how neurons can endocytose whole silicon nanowires or parts of them, monitoring and even modulating neuronal activity. Charles Lieber was a colleague of Robert Langer. Together, along with Daniel S. Kohane, they worked on a paper describing artificial tissue scaffolds that could be implanted in a human heart to monitor its activity remotely. Robert Langer, an MIT alumnus and expert in nanotech drug delivery, is one of the co-founders of Moderna. His net worth is now $5.1 billion USD thanks to Moderna’s mRNA-1273 vaccine sales. Both Charles Lieber and Robert Langer’s bibliographies describe, essentially, techniques for human enhancement, i.e. transhumanism. Klaus Schwab, the founder of the World Economic Forum and the architect behind the so-called “Great Reset”, has long spoken of the “blending of biology and machinery” in his books. Since these revelations, it has come to the attention of independent researchers that the COVID-19 vaccines may contain reduced graphene oxide nanoparticles. Japanese researchers have also found unexplained contaminants in COVID-19 vaccines. Graphene oxide is an anxiolytic. It has been shown to reduce the anxiety of laboratory mice when injected into their brains. Indeed, given SARS-CoV-2 Spike’s propensity to compromise the blood-brain barrier and increase its permeability, it is the perfect protein for preparing brain tissue for extravasation of nanoparticles from the bloodstream and into the brain. Graphene is also highly conductive and, in some circumstances, paramagnetic. In 2013, under the Obama administration, DARPA launched the BRAIN Initiative; BRAIN is an acronym for Brain Research Through Advancing Innovative Neurotechnologies®. This program involves the development of brain-computer interface technologies for the military, particularly non-invasive, injectable systems that cause minimal damage to brain tissue when removed. Supposedly, this technology would be used for healing wounded soldiers with traumatic brain injuries, the direct brain control of prosthetic limbs, and even new abilities such as controlling drones with one’s mind. Various methods have been proposed for achieving this, including optogenetics, magnetogenetics, ultrasound, implanted electrodes, and transcranial electromagnetic stimulation. In all instances, the goal is to obtain read or read-write capability over neurons, either by stimulating and probing them, or by rendering them especially sensitive to stimulation and probing. However, the notion of the widespread use of BCI technology, such as Elon Musk’s Neuralink device, raises many concerns over privacy and personal autonomy. Reading from neurons is problematic enough on its own. Wireless brain-computer interfaces may interact with current or future wireless GSM infrastructure, creating neurological data security concerns. A hacker or other malicious actor may compromise such networks to obtain people’s brain data, and then exploit it for nefarious purposes. However, a device capable of writing to human neurons, not just reading from them, presents another, even more serious set of ethical concerns. A BCI that is capable of altering the contents of one’s mind for innocuous purposes, such as projecting a heads-up display onto their brain’s visual center or sending audio into one’s auditory cortex, would also theoretically be capable of altering mood and personality, or perhaps even subjugating someone’s very will, rendering them utterly obedient to authority. This technology would be a tyrant’s wet dream. Imagine soldiers who would shoot their own countrymen without hesitation, or helpless serfs who are satisfied to live in literal dog kennels. BCIs could be used to unscrupulously alter perceptions of basic things such as emotions and values, changing people’s thresholds of satiety, happiness, anger, disgust, and so forth. This is not inconsequential. Someone’s entire regime of behaviors could be altered by a BCI, including such things as suppressing their appetite or desire for virtually anything on Maslow’s Hierarchy of Needs. Anything is possible when you have direct access to someone’s brain and its contents. Someone who is obese could be made to feel disgust at the sight of food. Someone who is involuntarily celibate could have their libido disabled so they don’t even desire sex to begin with. Someone who is racist could be forced to feel delight over cohabiting with people of other races. Someone who is violent could be forced to be meek and submissive. These things might sound good to you if you are a tyrant, but to normal people, the idea of personal autonomy being overridden to such a degree is appalling. For the wealthy, neural laces would be an unequaled boon, giving them the opportunity to enhance their intelligence with neuroprosthetics (i.e. an “exocortex”), and to deliver irresistible commands directly into the minds of their BCI-augmented servants, even physically or sexually abusive commands that they would normally refuse. If the vaccine is a method to surreptitiously introduce an injectable BCI into millions of people without their knowledge or consent, then what we are witnessing is the rise of a tyrannical regime unlike anything ever seen before on the face of this planet, one that fully intends to strip every man, woman, and child of our free will. Our flaws are what make us human. A utopia arrived at by removing people’s free will is not a utopia at all. It is a monomaniacal nightmare. Furthermore, the people who rule over us are Dark Triad types who cannot be trusted with such power. Imagine being beaten and sexually assaulted by a wealthy and powerful psychopath and being forced to smile and laugh over it because your neural lace gives you no choice but to obey your master. The Elites are forging ahead with this technology without giving people any room to question the social or ethical ramifications, or to establish regulatory frameworks that ensure that our personal agency and autonomy will not be overridden by these devices. They do this because they secretly dream of a future where they can treat you worse than an animal and you cannot even fight back. If this evil plan is allowed to continue, it will spell the end of humanity as we know it. Conclusions: The current pandemic was produced and perpetuated by the establishment, through the use of a virus engineered in a PLA-connected Chinese biowarfare laboratory, with the aid of American taxpayer dollars and French expertise. This research was conducted under the absolutely ridiculous euphemism of “gain-of-function” research, which is supposedly carried out in order to determine which viruses have the highest potential for zoonotic spillover and preemptively vaccinate or guard against them. Gain-of-function/gain-of-threat research, a.k.a. “Dual-Use Research of Concern”, or DURC, is bioweapon research by another, friendlier-sounding name, simply to avoid the taboo of calling it what it actually is. It has always been bioweapon research. The people who are conducting this research fully understand that they are taking wild pathogens that are not infectious in humans and making them more infectious, often taking grants from military think tanks encouraging them to do so. These virologists conducting this type of research are enemies of their fellow man, like pyromaniac firefighters. GOF research has never protected anyone from any pandemic. In fact, it has now started one, meaning its utility for preventing pandemics is actually negative. It should have been banned globally, and the lunatics performing it should have been put in straitjackets long ago. Either through a leak or an intentional release from the Wuhan Institute of Virology, a deadly SARS strain is now endemic across the globe, after the WHO and CDC and public officials first downplayed the risks, and then intentionally incited a panic and lockdowns that jeopardized people’s health and their livelihoods. This was then used by the utterly depraved and psychopathic aristocratic class who rule over us as an excuse to coerce people into accepting an injected poison which may be a depopulation agent, a mind control/pacification agent in the form of injectable “smart dust”, or both in one. They believe they can get away with this by weaponizing the social stigma of vaccine refusal. They are incorrect. Their motives are clear and obvious to anyone who has been paying attention. These megalomaniacs have raided the pension funds of the free world. Wall Street is insolvent and has had an ongoing liquidity crisis since the end of 2019. The aim now is to exert total, full-spectrum physical, mental, and financial control over humanity before we realize just how badly we’ve been extorted by these maniacs. The pandemic and its response served multiple purposes for the Elite: Concealing a depression brought on by the usurious plunder of our economies conducted by rentier-capitalists and absentee owners who produce absolutely nothing of any value to society whatsoever. Instead of us having a very predictable Occupy Wall Street Part II, the Elites and their stooges got to stand up on television and paint themselves as wise and all-powerful saviors instead of the marauding cabal of despicable land pirates that they are. Destroying small businesses and eroding the middle class. Transferring trillions of dollars of wealth from the American public and into the pockets of billionaires and special interests. Engaging in insider trading, buying stock in biotech companies and shorting brick-and-mortar businesses and travel companies, with the aim of collapsing face-to-face commerce and tourism and replacing it with e-commerce and servitization. Creating a casus belli for war with China, encouraging us to attack them, wasting American lives and treasure and driving us to the brink of nuclear armageddon. Establishing technological and biosecurity frameworks for population control and technocratic- socialist “smart cities” where everyone’s movements are despotically tracked, all in anticipation of widespread automation, joblessness, and food shortages, by using the false guise of a vaccine to compel cooperation. Any one of these things would constitute a vicious rape of Western society. Taken together, they beggar belief; they are a complete inversion of our most treasured values. What is the purpose of all of this? One can only speculate as to the perpetrators’ motives, however, we have some theories. The Elites are trying to pull up the ladder, erase upward mobility for large segments of the population, cull political opponents and other “undesirables”, and put the remainder of humanity on a tight leash, rationing our access to certain goods and services that they have deemed “high-impact”, such as automobile use, tourism, meat consumption, and so on. Naturally, they will continue to have their own luxuries, as part of a strict caste system akin to feudalism. Why are they doing this? Simple. The Elites are Neo-Malthusians and believe that we are overpopulated and that resource depletion will collapse civilization in a matter of a few short decades. They are not necessarily incorrect in this belief. We are overpopulated, and we are consuming too many resources. However, orchestrating such a gruesome and murderous power grab in response to a looming crisis demonstrates that they have nothing but the utmost contempt for their fellow man. To those who are participating in this disgusting farce without any understanding of what they are doing, we have one word for you. Stop. You are causing irreparable harm to your country and to your fellow citizens. To those who may be reading this warning and have full knowledge and understanding of what they are doing and how it will unjustly harm millions of innocent people, we have a few more words. Damn you to hell. You will not destroy America and the Free World, and you will not have your New World Order. We will make certain of that. *  *  * This PDF document contains 14 pages, followed by another 17 pages of references. For those, please visit the original PDF file at Covid19 – The Spartacus Letter. *  *  * We try to run the Automatic Earth on donations. Since ad revenue has collapsed, you are now not just a reader, but an integral part of the process that builds this site. Thank you for your support. Support the Automatic Earth in virustime. Donate with Paypal, Bitcoin and Patreon. Tyler Durden Mon, 09/27/2021 - 00:00.....»»

Category: dealsSource: nyt3 hr. 31 min. ago

How to tell if you"re a covert narcissist

Our work-advice columnist tells a reader how to tell if they're a narcissist, plus a look inside Launch House's work-hard-play-hard culture, in Insider Weekly. Welcome back to Insider Weekly! I'm Matt Turner, co-EIC of business at Insider."Am I a covert narcissist?"That's the question at the heart of Rebecca Knight's latest work-advice column this week. Rebecca's spent her career answering these kinds of questions, most often focused on the emotional life of work. As boundaries between home and work blur in the WFH era, they're more relevant than ever.Also in this week's newsletter:Noom markets itself as an anti-diet app. Users say they count calories and receive generic advice from expensive subscriptions.Private-equity firms are locked in a power struggle with their investors, and lawyers are raking in cash no matter what.Launch House allows startup founders to live and work in mansions. Now it's facing scrutiny over safety.Let me know what you think of all our stories at mturner@insider.comSubscribe to Insider for access to all our investigations and features. New to the newsletter? Sign up here. Download our app for news on the go - click here for iOS and here for Android.From narcissism to hybrid life, our work-life columnist tackles tough questions 20th Century Fox Correspondent Rebecca Knight takes us behind the scenes of her work-life column What's Working?:What most interests me about work and careers are the people-problems. When launching my column, "What's Working?", I wanted to find a way to talk about these things and help workers through the challenges they face.Work and home have merged into one in this pandemic. There is much more of an acknowledgement and a focus on what's going on in our personal lives outside of work. The reader questions I'm getting most often are about personality clashes in the remote setup and about people reassessing what they want out of their lives and out of their jobs.My most memorable column so far was about remote-work paranoia. A reader worried: "There must be another Slack channel that everyone else is having fun on and leaving me out of." That reader tapped into something that a lot of us are feeling right now - and as a remote employee myself, I sometimes feel it, too.So that's why it's important to remember that we're all doing our best in this pandemic. Have compassion for yourself and for others. And if you need any advice, send me a question at rknight@insider.com.Read Rebecca's latest column here: 'I always thought that I was a socially anxious introvert. Now I worry I'm a narcissist. What do I do?'Noom says it offers personalized weight-loss support. Users say otherwise. Noom An industry leader in weight-loss apps, Noom has millions of dollars worth of venture-capital funding. It claims to use psychological methods and customized plans to help users lose weight - though users say they largely get cookie-cutter content. While the app sells itself on a concept of psychological reset and long-term weight control, a registered dietician said Noom advises an extremely low daily calorie goal - "It's not really an adult serving size." Here's why some clients reported feeling anxious and burnt out. Get the full story on Noom's canned advice and expensive subscription service.Private-equity firms are locked in a power struggle with their investors Samantha Lee/Insider Private-equity firms and their investors are at each other's throats with expensive demands and competing interests. Legal teams from both parties are caught in the middle, waging a secret war that investor attorneys see as "a game of holding the line." Ambiguous contractual changes between legal teams, firms, and investors muddy the water, and changes are rarely uniform across the industry. The back-and-forth often results in seven-figure legal expenses, as private-equity-firm billing rates can cost up to $1,500 per hour. But the battle, according to one attorney who works for investors, is one-sided in favor of private-equity.Read about the expensive legal war between private-equity firms and their investorsA wild party and COVID outbreak have raised safety concerns for Launch House Eray Alan Los Angeles startup Launch House, a coliving program meant for founders, threw a mismanaged house party with hundreds of guests. Police had to shut it down - but that's part of the "work hard, play hard" ethos of Launch House, according to former residents.While at times, Launch House was poorly controlled and potentially unsafe, with COVID-19 outbreaks and parties, residents also said there were many benefits. A strong community, invaluable network, and fireside chats with like-minded entrepreneurs all remain part of the culture. But the safety concerns have put the company under scrutiny.This is how Launch House plans to move forward - with the help of venture capitalists.More of this week's top reads:Better's CEO has a specific hiring philosophy that allowed him to quadruple its workforce during the pandemic.These 9 BlackRock execs are powering Aladdin, a powerful behind-the-scenes tech software the asset manager has staked its future on.Shopify beat Amazon in one important metric, as competition intensifies between the e-commerce giants.Insider correspondent Kate Taylor exposed Brandy Melville's allegations of discrimination and sexual exploitation. Here's how she got the story. Alphabet life-sciences unit Verily is planning to untangle itself from Google ahead of a potential IPO.This Stitch Fix employee quit during a fiery all-hands meeting. She says stylists are being manipulated and silenced.Investors of cannabis startup Civilized are pushing out the founders. Insider has the full memo.Compiled with help from Phil Rosen, Lisa Ryan and Jordan Erb.Read the original article on Business Insider.....»»

Category: worldSource: nyt21 hr. 47 min. ago

Meet the entrepreneur planning to build the "McDonald"s" of plant-based burgers

Steele Smiley has 20 years of experience in the wellness industry. His latest act: tapping into the millennial and Gen Z plant-based food market. Steele Smiley, founder of fast casual restaurants Crisp & Green and Stalk & Spade. Crisp & Green Entrepreneur Steele Smiley aims to build America's first plant-based burger chain, Stalk & Spade. Along with his other fast-casual restaurant, Crisp & Green, Smiley is tapping into a healthy eating market dominated by millennials and Gen Z. He spoke with Insider about how the pandemic has shifted people's mindset toward wellness. See more stories on Insider's business page. Steele Smiley will be the first to tell you he runs his life like he's in the military.That involves 20 workouts a week, three times a day: Running in the morning, a yoga or boxing class during the day, and lifting weights at night. Since that doesn't seem to satisfy all his energy, Smiley also juggles two Minnesota-based fast-casual restaurants. In 2016, he opened Stalk & Spade, which serves up salads, grain bowls, smoothies, and free workout classes. Five years later (in the midst of the pandemic) he launched Crisp & Green with a plant-based-only menu. He's expanded both brands in the south and Midwest, bucking conventional health hubs like LA and NYC in favor of an edge in less competitive markets."We intend to become the first franchisable plant-based burger chain in the country," Smiley told Insider, billing it as the plant-based version of McDonald's.It's a bold statement, but the 43-year-old serial entrepreneur has 20 years in the fitness industry under his belt. While he declined to share revenue numbers, analytics verified by Insider showed that Crisp & Green digital orders increased from 9% of its total orders in January 2020 to more than 70% in April when the pandemic hit, where they've stayed ever since. Stalk & Spade launched in May. Stalk & Spade In 2021 alone, Crisp & Green expanded from five states to 12, with several locations in the Sun Belt, an area seeing explosive growth before and during the pandemic. Smiley said the chain is nearing 100 stores in 14 states, with new locations opening every 6.8 days. Overall, however, the restaurant scene has been struggling. Last August, before widespread vaccination, the fast casual space was down 12%, according to figures from foodservice data platform Technomic. While consumer spending in restaurants rose this year compared to last, recovery hasn't yet snapped back to pre-pandemic traffic levels. Restaurants are still contending with issues like labor shortages and shorter hours.Still, the wellness economy is worth $1.5 trillion, according to McKinsey, and Smiley is betting he can tap into that, especially since the pandemic has prompted many people to adopt a healthier lifestyle. Plant-based diets, which nearly 10 million Americans follow, are gaining traction. The market is growing, expected to exceed $74 billion by 2021."The next evolution of healthy eating is plant-based eating," Smiley said. "Within a decade, people will choose the plant-based alternatives of the traditional meat they eat today."Move over, SweetgreenSmiley had just $765 in his bank account when he kicked off his career in 2004 with his boutique studio STEELE Fitness. In 2013, he had just landed a major partnership with Under Armour when he sold his business to international wellness company Lift Brands Global. He joined the parent company as a senior executive.He launched Crisp & Green in November 2016, which he juggled while working for Lift Brands for five months before going full-time. "I would work during the day at my first big business, and at night I would put on a Crisp & Green t-shirt and work at my restaurant," Smiley said.Smiley said he'd always wanted to launch multiple businesses in multiple industries. Evolving his career from fitness to healthy eating was only a natural next step."The opportunity that I felt was staring me in the face was food," he said. "In fitness, I taught people that the hour you work out can only be so impactful. The other 23 hours of a day, you can help people understand how to make the right food choices." Crisp & Green offers free fitness classes in addition to its salad and smoothie menu. Crisp & Green Those who perhaps best understood this pre-pandemic were young, healthy women, whom Steele would often see walking through Crisp & Green's doors.His brands certainly have Gen Z and millennial written all over them. The two generations helped grow the global healthy eating and nutrition economy to $704 billion and are leading the way in plant-based eating. Millennials, dubbed "the wellness generation," are especially more health-conscious and more willing to spend on healthy food and fitness than their parents.For them, investing in green juices and $30 spin classes is a discreet status symbol, a way to convey they care about their health and have the money to do it properly.Smiley made sure Crisp & Green checked all the boxes for this demographic: healthy, digitally accessible, deliverable, and Instagrammable. "It made people say I want to live a more aspirational life," he said. A post shared by C&G • Healthy & Scratch-Made! (@crispandgreen) It's this combination that Smiley believes enabled the restaurant to gain steam during the pandemic, which in turn led to his confidence in launching another venture."I figured why stop with just one that was working?" he said. And so Stalk & Spade was born.The plant-based way of the futureAfter his pandemic success, Smiley said he saw an opportunity to prepare for a post-vaccine economic reopening by giving Americans what he thought they'd need after a health-related recession and a social recession: healthier food and an opportunity to get out of the house.But he recognized that bringing yet another concept into the increasingly saturated wellness sector - especially during a pandemic that saw a declining footprint in the fast casual industry - meant that he'd be facing a tough road. He knew he needed to look toward the future - and what he saw were plants. A post shared by STALK & SPADE (@stalkandspade) He said he and his team worked on building Stalk & Spade's plant-based menu from scratch until taste testers couldn't discern the difference between a real burger and a plant-based one.The pandemic pushed healthy eating 10 years into the future, he said. It dramatically expanded his demographic from mostly young adults to nearly everyone.When asked who his clientele is now, Smiley said with a laugh, "humans." After all, "everyone wants to live a better life."Nutrition has taken on new importance, per a McKinsey survey, as people now want food that will help them accomplish wellness goals while tasting good. Millennials and Gen Z are even more willing to invest in health and wellness post-pandemic, with 60% believing that taking care of one's health will be the pandemic's most important societal change. With a modern, minimalist design, even Stalk & Spade's interior is Instagrammable. Stalk & Spade The mental shift has sparked the rise of a high-performance lifestyle, in which people are increasingly letting wearables and apps track their health and make lifestyle choices for them. That includes Smiley himself, who monitors his sleep with wearables. The healthier life people are now turning to is the life Smiley has been living this whole time, which could prove to be the key to growing his brands.By the end of the year, he said, Crisp & Green will have 25 locations with another 60 in the pipeline. Stalk & Spade is set to open up its second Minnesota location in early 2022.Smiley believes the time is now for plant-based eating to go from a niche audience to a more mainstream one. "We fed into the trends of healthy eating," he said of the plant-based market. "It's an opportunity for an entire new genre to start."Read the original article on Business Insider.....»»

Category: topSource: businessinsiderSep 25th, 2021

Visualizing The World"s Biggest Pharmaceutical Companies

Visualizing The World's Biggest Pharmaceutical Companies Some of the world’s biggest pharmaceutical companies have played a central role in the COVID-19 pandemic. However, it’s likely no surprise that the pandemic has also been great for many healthcare businesses. In fact, as Visual Capitalist's Anshool Deshmukh notes, in 2020 alone, the world’s 50 largest pharmaceutical companies still combined for a whopping $851 billion in revenues. In this graphic, using data from Companies Market Cap, we list the largest pharmaceutical companies in the world by market capitalization. It’s worth noting this list also includes healthcare companies that work closely with pharmaceuticals, including biotech, pharmaceutical retailers, clinical laboratories, etc. Editor’s Note: A previous version of this graphic was missing some key companies such as GSK and AbbVie. They were unfortunately not included in the original source and we are now working to make sure there were no other smaller omissions. Thanks to all that sent in corrections. The Pharmaceutical Leaders To start, here are the top five biggest pharmaceutical companies in the world at the moment by market capitalization: 1. Johnson & Johnson The pharmaceutical and consumer goods giant is worth $428.7 billion in market cap. They developed the third vaccine authorized for use in the U.S. and were named among the TIME100 Most Influential Companies List in 2021. 2. Roche The Swiss pharmaceutical giant is at the forefront of oncology, immunology, infectious diseases, ophthalmology, and neuroscience. In 2019, Roche’s pharma segment sales rose by a healthy 16% to $53 billion. 3. Pfizer Despite being the leading COVID-19 vaccine manufacturer in North America, Pfizer slid in the rankings to third place. The company has recently gained momentum, especially in the past quarter, with Q2’2021 revenues of $19.0 billion, reflecting a 86% operational growth from 2020. 4. Eli Lilly Eli Lilly has taken a significant step towards establishing itself as a pharmaceutical industry leader. Having a market cap value of $125 billion in 2019, Eli Lilly has jumped to a current value of $214.9 billion, a significant growth of 72%. 5. Novartis The second-biggest pharmaceutical company out of Switzerland, Novartis has been the face of the pharma industry for about 25 years. The primary manufacturer for the most recognizable drugs on the market pulled in a revenue of over $48 billion in 2020, a 3% increase compared to 2019. Here’s how all the biggest pharmaceutical companies in the world stack up against each other:   World’s Largest Pharmaceutical Exporters and Importers   According to the World Trade Organization (WTO), these countries exported the most number of pharmaceuticals in the year 2019:   In contrast, here are the biggest importers over the same period.     This position is hardly surprising for the U.S., where six of the world’s top 10 pharmaceutical companies are headquartered. The country also captures 45% of the global market.   The Future of Pharmaceutical Companies If the response to the COVID-19 pandemic has taught us anything, it is that in building a patient-centered future, the pharmaceutical industry plays a key role. It has to constantly find new ways to customize medicines while researching and developing new tools and drugs. By embracing disruptive technologies like 3D printed drugs, artificial intelligence guided therapies, and preventive medicine while working with regulatory agencies, the pharmaceutical companies will benefit from having a digital revolution. Furthermore, emerging markets will have a more significant say in the global pharmaceutical market in the coming years. Even though ‘big pharma’ will keep raking in the massive profits they do every year, their reliance on countries like Brazil and India for research and drug production will significantly impact the years to come. Tyler Durden Fri, 09/24/2021 - 23:40.....»»

Category: blogSource: zerohedgeSep 25th, 2021

Every Star Wars movie and show you can stream on Disney Plus - from "A New Hope" to "Visions"

Disney Plus includes every major Star Wars movie, along with exclusive series like "The Mandalorian" and "Visions." When you buy through our links, Insider may earn an affiliate commission. Learn more. Disney Plus has a huge selection of Star Wars content. Alyssa Powell/Business Insider Disney Plus has every Star Wars movie from the original trilogy through "The Rise of Skywalker." The service is also home to exclusive Star Wars shows, like "The Mandalorian" and "Visions." Disney Plus costs $8/month or $80/year, and you can bundle it with ESPN+ and Hulu for $14/month. Monthly Subscription Service (small)Disney Plus is home to a large collection of movies and TV shows from all of the studio's major brands, including the Star Wars franchise. You can sign up for $8 a month or $80 a year. Every Star Wars movie, from 1977's "A New Hope" to 2019's "The Rise of Skywalker," is available to watch right now on Disney Plus. New original Star Wars shows are also available to stream, and a full slate of movies and series have been revealed for the coming years.If you're a Star Wars fan looking for your favorite title to watch, we broke down all the basics you need to know about streaming Star Wars on Disney Plus.What Star Wars movies and shows can I stream on Disney Plus?Disney Plus features every major Star Wars movie released so far. This includes all of the episodic entries in the franchise, from "A New Hope" through "The Rise of Skywalker." All of the movies are available in 4K HDR with Dolby Vision and Dolby Atmos on supported devices.In addition to the movies, Disney Plus offers access to several Star Wars shows, including the original series "The Mandalorian." The service is also home to animated Star Wars shows, like "The Clone Wars," "Rebels," "The Bad Batch," and "Visions." Other upcoming series include a live-action show focused on Obi-Wan Kenobi and another focused on Anakin Skywalker's student Ahsoka. Multiple "Star Wars" movies have been announced as well, including one based on the comic book and video game series "Rogue Squadron," and another created by "Thor: Ragnarok" director Taika Waititi.Between all of the currently available Star Wars titles and all of the upcoming shows, there is a ton to stream. With that in mind, we've listed every Star Wars movie and show announced for Disney Plus so far.Here are all the Star Wars movies and shows on Disney Plus: Star Wars movies currently available on Disney Plus: Disney "Star Wars Episode I: The Phantom Menace""Star Wars Episode II: Attack of the Clones""Star Wars Episode III: Revenge of the Sith""Star Wars Episode IV: A New Hope""Star Wars Episode V: The Empire Strikes Back""Star Wars Episode VI: Return of the Jedi""Star Wars Episode VII: The Force Awakens""Star Wars Episode VIII: The Last Jedi""Star Wars Episode IX: The Rise of Skywalker""Rogue One: A Star Wars Story""Solo: A Star Wars Story" "Empires of Dreams: The Story of the Star Wars Trilogy" (the 2004 documentary film directed by Kevin Burns)Monthly Subscription Service (small) 'Star Wars: Visions' - now available Disney "Visions" is a collection of 10 animated short films set in the "Star Wars" universe. The films are developed by Japanese anime creators, which gives them a distinct look from Western "Star Wars" media. The show is similar in scope to "The Animatrix," a series of nine anime short films set in "The Matrix" universe, and "Batman: Gotham Knight," a set of six animated Batman shorts set in Japan.The anthology collection premiered on Disney Plus on September 22 with both English and Japanese voices. Monthly Subscription Service (small) 'The Bad Batch' - available now Disney 'The Bad Batch" is an animated series following a group of elite Republic soldiers in the aftermath of "The Clone Wars." While the Republic troopers are clones of bounty hunter Jango Fett, each member of the Bad Batch has unique genetic skills that help contribute to the team.'The Bad Batch" premiered with a special 70-minute episode on May 4, Star Wars Day, and ran for 16 episodes during its first season. Disney has already announced that a second season will arrive in 2022.Monthly Subscription Service (small) 'The Mandalorian' - available now "The Mandalorian" Disney Plus Set five years after the fall of the Empire in the original "Star Wars" trilogy, "The Mandalorian" focuses on a bounty hunter who finds himself on a mission to protect a creature with a powerful connection to the Force.Director Jon Favreau ("Lion King" and "Iron Man") is the creator, head writer, showrunner, and co-executive producer of the series, which stars Pedro Pascal as the Mandalorian alongside Gina Carano, Nick Nolte, Giancarlo Esposito, Emily Swallow, and Carl Weathers.Two full seasons of "The Mandalorian" are now available to stream. A third season is in development, and the show sparked multiple spin-off series, including "Ahsoka" and "The Book of Boba Fett," the latter of which is expected to debut on Disney Plus in December 2021. Monthly Subscription Service (small) 'Star Wars: The Clone Wars' - available now Disney All seven seasons of "Star Wars: The Clone Wars" are now streaming on Disney Plus.The animated show originally came to an end after its sixth season back in 2014, but Disney revived the series for one final season on Disney Plus.  Season seven consists of 12 episodes. Monthly Subscription Service (small) 'Disney Gallery: The Mandalorian' - available now The creators and cast of "The Mandalorian" celebrating the series' premiere. Reuters This eight-part documentary series offers a behind-the-scenes look at the production of "The Mandalorian." The show includes interviews, never-before-seen footage, and roundtable conversations with the cast and crew. Executive Producer Jon Favreau serves as the documentary's host.Monthly Subscription Service (small) Other Star Wars series currently available on Disney Plus: The LEGO Star Wars games and TV series have become fan favorites. TT Games "Star Wars: Rebels""Star Wars Resistance""Star Wars: The Resistance Rises""Star Wars Holiday Special""Star Wars Blips""Star Wars: Forces of Destiny""Star Wars Galaxy's Edge: Adventure Awaits" "Star Wars Vintage: Clone Wars (2D Microseries)"Star Wars: Ewoks""Star Wars: The Story of the Faithful Wookie""Star Wars: Ewoks The Battle for Endor""Star Wars: Caravan of Courage""LEGO Star Wars All Stars""LEGO Star Wars The Freemaker Adventures""LEGO Star Wars: Droid Tales""LEGO Star Wars: The New Yoda Chronicles""The LEGO Star Wars Holiday Special"Monthly Subscription Service (small) 'The Book of Boba Fett' - December 2021 Disney Temuera Morrison returns to his role as Boba Fett, the iconic bounty hunter from the original trilogy. "The Book of Boba Fett" comes decades after the character was presumed dead in "Star Wars: Return of the Jedi," and will follow Fett's ascension as the leader of the criminal underworld on Luke Skywalker's home planet of Tatooine.Monthly Subscription Service (small) 'Ahsoka' - TBA Disney Plus Ahsoka is a Jedi first introduced in "The Clone Wars" animated series, but the Disney Plus show will feature an adult version of the character played by Rosario Dawson.Ahsoka made her first live-action appearance during season two of "The Mandalorian." The new series focuses on a villain named Grand Admiral Thrawn, a name that's quite familiar with fans of "Star Wars" comic books and extended universe novels. Disney has not announced a premiere date yet. Monthly Subscription Service (small) Obi-Wan Kenobi Project - TBA Ewan McGregor as Obi-Wan Kenobi in "Star Wars: Episode III - Revenge of the Sith" 20th Century Fox One of the most anticipated Star Wars projects boasts the return of Ewan McGregor in the role of Obi-Wan Kenobi.The as-yet-untitled Kenobi series is set eight years after the events of "Star Wars: Revenge of the Sith." Following several delays, the show is now scheduled to premiere in 2022. Deborah Chow is attached to direct the series. Chow previously directed two episodes of "The Mandalorian."Monthly Subscription Service (small) 'Andor' - TBA Disney "Andor" is a spy thriller with Diego Luna reprising his role as Cassian Andor from 2016's "Rogue One." Alan Tudyk also stars as the voice behind the droid K-2SO. As of publication time, there is no date for when this will be released.Monthly Subscription Service (small) 'Lando' - TBA Lucasfilm Lando Calrissian, the classic "Star Wars" character played by Billy Dee Williams and Donald Glover, will star in his own Disney Plus series led by "Dear White People" and "Bad Hair" director Justin Simien. Monthly Subscription Service (small) Untitled film from Taika Waititi - TBA Director and writer Taika Waititi won his first Oscar for 'Jojo Rabbit.' Photo by Evan Agostini/Invision/AP Taika Waititi, award-winning director of films like "Thor Ragnarok" and "Jojo Rabbit," is developing his own film set in the "Star Wars" universe. Waititi's previously worked on "The Mandalorian," voicing the droid character IG-11 and directing the finale of season one.Monthly Subscription Service (small) 'Rangers of the New Republic' - TBA Disney "Rangers of the New Republic" is a new series created by "The Mandalorian" showrunners Jon Favreau and Dave Filoni. The show is expected to connect with "The Mandalorian" and "Ahsoka," but it's not clear if the new series will feature any existing characters from the "Star Wars" universe. A release date has not been announced yet.Monthly Subscription Service (small) 'The Acolyte' - TBA Disney Disney describes 'The Acolyte" as a mystery-thriller that explores the dark side of the Force in the final days of the High Republic, an era that came hundreds of years before the "Star Wars" films. Leslye Headland, a co-creator of the Netflix series "Russian Doll," will write and produce the show.Monthly Subscription Service (small) 'Rogue Squadron' - Christmas 2023 Disney 'Rogue Squadron" is a new film coming in 2023 from "Wonder Woman" director Patty Jenkins. The "Rogue Squadron" name has been used for comic books and video games that focus on the Republic's ace pilots. While details on the film are slim, you can expect plenty of high-flying starfighter battles based on the name alone.Monthly Subscription Service (small) 'A Droid Story' - TBA 20th Century Fox via YouTube screengrab R2-D2 and C-3PO, the lovable robots who accompany the 'Star Wars' heroes across multiple adventures, will receive their own animated film, 'A Droid Story.' Monthly Subscription Service (small) Disney Plus FAQs What is Disney Plus and how much does it cost?Disney Plus is Disney's on-demand streaming service with two types of plans. An annual subscription costs $80 a year, while a monthly subscription costs $8 a month. You can also sign up for a bundle with ESPN+ and Hulu for $14 a month.Here is a full breakdown of the prices.Each membership gets you ad-free streaming and unlimited downloads for a growing collection of movies and shows from Disney, Pixar, Marvel, Star Wars, National Geographic, and 20th Century Fox.Read everything else you should know about Disney Plus here:Disney Plus: All your questions answered about Disney's ad-free streaming serviceDisney Plus costs $8 a month on its own, but you can bundle it with Hulu and ESPN+ for an extra $6All the kids' movies you can stream on Disney Plus — from 'Snow White' to 'Frozen'All the new kids' shows you can watch on Disney Plus — from 'Vampirina' to the new reboot of 'Star Wars: The Clone Wars'All the new shows you can watch on Disney Plus — from 'The Mandalorian' to 'WandaVision'All the Marvel movies and shows you can stream on Disney Plus — from "Iron Man" to the new 'Loki'All the Pixar films and shorts you can stream on Disney Plus — from 'Toy Story' to 'Inside Out' Read the original article on Business Insider.....»»

Category: worldSource: nytSep 24th, 2021

Allstate CHRO details why the insurance leader is betting big on workforce technology

Carrie Blair, the EVP and CHRO of Allstate, told Insider how the insurance leader has calibrated its technological capabilities over the past year. Insider To boost efficiency and in-house capabilities, Allstate has introduced self-service and analytics tools for employees and managers. Allstate Carrie Blair has been EVP and CHRO at Allstate since October 2019. Over the past year, Allstate has been focusing on innovative technology experiences for employees. Blair said she works with the CIO and CFO to prioritize tech investments based on measurable outcomes. This article is part of the "Innovation C-Suite" series about business growth and technology shifts. For Carrie Blair, joining Allstate as the chief human resource officer in October 2019 was a no-brainer. After nearly 15 years in human resources positions at financial services companies, she was ready for a role at an iconic, purpose-driven, optimistic brand. "I can't think of anywhere I've traveled where someone hasn't said, 'Oh, they're the Good Hands people," Blair told Insider. But she was also energized by the idea that Allstate was clearly willing to disrupt and transform the insurance industry, both for consumers and employees. In general, she explained, insurance has fallen behind when it comes to technology innovation, but is catching up fast. Allstate, for example, now uses telematics to assess driving behavior; drones to survey catastrophes; and offers QuickFoto Claim to allow customers to assess car insurance claims for minor vehicle damage. For Allstate's employees, Blair's challenge has been how to prioritize and implement consumer-grade, innovative technology experiences for people inside the company, while still being aggressive with consumer offerings. A new approach to technology and HR"Recently, we've really started taking a look at our entire approach to technology and HR," she said. In the past, for example, the company might have bought tools for talent acquisition, or performance management, but they did not necessarily work well together or across the ecosystem. Now, Allstate's HR organization is working to deploy self-service tools for employees and managers for things that are frequently used or highly repetitive, Blair said, as well as analytics tools that offer them insights about their work patterns. "Every week I get a view that comes into my own personal inbox that tells me how I spent my time last week, how long I was in meetings, how much time I spent collaborating and how much time I had for focused, head-down work," she explained. Another tool offers the organization a full view across the enterprise to understand how and where people are working, which helps inform decisions around real estate in a new, hybrid workplace. For example, the types of collaboration rooms they need and where they should be located. The company has also started using a digital workspace called MURAL. The platform offers a shared digital canvas for visual collaboration, as well as Zoom Rooms, which uses AI-driven face recognition technology to bring hybrid teams, including those together in person, into Zoom meetings. "It creates this level playing field, which stops the in-person group from simply talking to each other and brings remote workers fully into the meeting," she said. All of these tools, she explained, are about testing and learning in the HR space around the most recent technology trends, with a focus on investing in people. "Human capital is always the most important thing," she said. "After all, we don't really produce anything, we deliver services and solutions to customers that depend on people." Technology innovation accelerated by the pandemicThe focus on technology innovation targeting employees was accelerated by the pandemic, said Blair, who began her role at Allstate only six months after COVID-19 shutdowns began. "Our IT team had been investing in our technology stack for a number of years, so we were able to get 95% of our folks working from home within days, around the world," she said. While only 20% of Allstate's workforce worked from home pre-pandemic, she said that under a new hybrid workforce model, that number will permanently rise to over 70%. "We've seen huge increases in applications because of that," Blair said. "It's been a positive outcome that people don't have to be tethered to an office anymore, because we have seen a 30% rise in diverse candidates applying for opportunities, and we can go to markets we never would have been in before." That includes targeting hard-to-find technology talent in places like Miami where Allstate does not have a physical presence, she explained. Blair added that she has worked closely with other C-suite executives, such as the CIO and CFO, around technology innovation, particularly around changing the funding model for technology investments to make sure it focuses on outcomes rather than annual financial cycles. "It will allow us to iterate as we go and get learnings faster," she said. "It also will allow us to put our Allstate hat on and say, 'As we look across the system, what is the best thing for the company?'" Read the original article on Business Insider.....»»

Category: smallbizSource: nytSep 24th, 2021

Top Research Reports for Home Depot, salesforce & Pfizer

Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), salesforce.com, inc. (CRM), and Pfizer Inc. (PFE). Friday, September 24, 2021The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), salesforce.com, inc. (CRM), and Pfizer Inc. (PFE). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Shares of Home Depot have modestly outperformed the Zacks Retail Building Products industry over the past year (+28.5% vs. +25.8%). The Zacks analyst acknowledges the fact that the One Home Depot plan, which focuses on expanding supply chain, technology investments and digital enhancements has proved to be greatly beneficial for the company.Steady growth in Pro and DIY customer categories is another major catalyst for growth. It has also been effectively adapting to the demand for renovations and construction activities, driven by prudent investments. Increased penetration of lumber products and continued pressure from higher transportation costs are major concerns though. The company also witnessed year-over-year moderation in its comparable store sales growth in second-quarter fiscal 2021.(You can read the full research report on Home Depot here >>>)salesforce shares have gained +37% in the last six months against the Zacks Computer Software industry’s gain of +29.4%. The Zacks analyst believes that diverse cloud offerings, clientele strength, strategic acquisitions and partnerships have been driving the company’s growth.salesforce’s sustained focus on introducing more aligned products and continued deal wins in the international market have been boosting its top line. Slack’s acquisition is also likely to position the company as a leader in the enterprise team collaboration solution space. Cut-throat competition, currency fluctuations and increased spending on international expansions and data centers have been weighing on the company’s near-term prospects though.(You can read the full research report on salesforce here >>>)Shares of Pfizer have gained +14.3% in the past three months against the Zacks Large-Cap Pharmaceuticals industry’s gain of +1.9%. The Zacks analyst believes that its sustainable pipeline with multiple late-stage programs is likely to drive growth.Its COVID-19 vaccine candidate has now been approved for emergency use in several countries, thereby becoming a key contributor to the top line. The Consumer Healthcare JV with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. Currency headwinds and pricing pressure, however, remain as major headwinds.(You can read the full research report on Pfizer here >>>)Other noteworthy reports we are featuring today include Sony Group Corporation (SONY), International Business Machines Corporation (IBM) and Zoetis Inc. (ZTS).Sheraz MianDirector of ResearchNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>> Time to Invest in Legal Marijuana If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027. After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%. You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.Today, Download Marijuana Moneymakers FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report salesforce.com, inc. (CRM): Free Stock Analysis Report International Business Machines Corporation (IBM): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report The Home Depot, Inc. (HD): Free Stock Analysis Report Zoetis Inc. (ZTS): Free Stock Analysis Report Sony Corporation (SONY): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksSep 24th, 2021

DELL Offers Long-Term Outlook, Launches Share Buyback Program

Dell (DELL) expects to witness revenue CAGR of 3-4% and earnings CAGR of more than 6% through fiscal 2026. The company launches a share buyback plan of $5 billion. Dell Technologies DELL provided a long-term outlook at its online Securities Analyst Meeting on Sep 23. The company expects to witness revenue CAGR of 3-4% and earnings CAGR of more than 6% through fiscal 2026.Net income to adjusted free cash flow conversion is expected to be greater than 100% through this period. Dell targets to return 40-60% of adjusted free cash flow to shareholders through share buybacks and quarterly dividend.In this aspect, Dell announced a share repurchase program worth $5 billion. Upon receiving approval from its board of directors post the VMware VMW spin-off, the company expects to start paying dividend, beginning first-quarter fiscal 2023. Currently, Dell expects to return $1 billion annually through dividend payment.Dell expects the VMware spin-off to complete in early November, subject to closing conditions, including favorable private letter ruling from the IRS.Dell shares increased 3.5% to $102.69 at close on Sep 23. Year to date, Dell shares are up 40.1% compared with the Zacks IT-Services return of 23.8%.Dell Technologies Inc. Price and Consensus Dell Technologies Inc. price-consensus-chart | Dell Technologies Inc. QuoteDell’s Prospects Powered by Edge, Telecom & Multi-CloudDell has been benefiting from strong PC sales due to solid demand for commercial PCs, driven by coronavirus-led remote-working and online-learning wave. Dell was ranked third by both Gartner and IDC among all PC vendors, trailing Lenovo LNVGY and HP HPQ in their latest second-quarter report.Dell now envisions Multi-cloud, Edge and Telecom as its next long-term growth drivers. In its presentation the company stated that 92% of companies are using multiple clouds while 82% uses hybrid cloud environments, up from 55% from five years ago.Edge presents a $110-billion market opportunity with estimated CAGR of 17% over 2020-2024. More than 50% of new IT infrastructure is expected to be deployed at Edge by 2023, which presents tremendous growth opportunity for Dell.Telecom is a $114-billion market opportunity, and is expected to witness a CAGR of 2% over 2020-2024. Dell’s strong partner base presents significant growth opportunities in the expanding 5G ecosystem.Dell’s served addressable market (including hardware, services and software) is currently worth $1.3 trillion and is expected to witness a CAGR of 6% between 2020 and 2024.Dells’ core market, which currently comprises of PC, peripherals, server, storage and hardware deployment and support, is worth $670 billion, and is expected to witness a CAGR of 3% through 2024.Extended markets that include IaaS, technology outsourcing, telecom networking, data management and system infrastructure software are valued at $650 billion and are expected to witness a CAGR of 8% through 2024.Revenue Outlook in DetailDell expects Infrastructure Solutions Group (“ISG”) revenues to grow in fiscal 2022 and 2023, driven by expanding total addressable market.        Dell expects ISG revenues to witness a CAGR of 3-5% through 2026 driven by server market share gain, multi-cloud, telecom and Edge.For Client Solutions Group (“CSG”) revenues are anticipated to witness a CAGR of 2-3% through 2026, driven by the work-from-anywhere trend and small & medium business growth.Dell maintained its third-quarter fiscal 2022 guidance. The company still expects revenues to increase in the mid-to-high teens range on a year-over-year basis and experience above-normal sequential growth.The Zacks Rank #3 (Hold) company expects strong CSG results, with revenues up in high-single digit, sequentially. ISG revenues are expected to grow low-single digit, sequentially. Time to Invest in Legal Marijuana If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027. After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%. You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.Today, Download Marijuana Moneymakers FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report HP Inc. (HPQ): Free Stock Analysis Report VMware, Inc. (VMW): Free Stock Analysis Report Dell Technologies Inc. (DELL): Free Stock Analysis Report Lenovo Group Ltd. (LNVGY): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksSep 24th, 2021

InMed Pharmaceuticals Inc. Releases FY 2021 Financial Report And Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has released its financial results and corporate update for FY 2021. In addition, the company announced a conference call and webcast, in which company leadership will discuss the report. Interested parties can access a replay of the webcast for 90 days. Corporate highlights of the report include the definitive agreement the company entered to acquire BayMedica Inc., a private company specializing in the manufacture and commercialization of rare cannabinoids; the announcement that INM’s IntegraSyn(TM) cannabinoid manufacturing approach had achieved a level of 2g/L cannabinoid yield, a signal of commercial viability; and the filing of clinical trial applications in multiple countries for the company’s multi-site Phase 2 clinical trial of INM-755 (cannabinol) cream in Epidermolysis Bullosa (“EB”). In addition, the company noted that it had notified the Toronto Stock Exchange about the voluntary delisting of its common shares, which were delisted in May 2021. INM also entered into a securities purchase agreement with an institutional investor designed to raise an estimated $12.0 million; INM closed the private placement on July 2, 2021. The company also reported a net loss of $10.2 million compared with a net loss of $8.9 million for the previous year, along with cash, cash equivalents, and short-term investments totaling $7.4 million, compared to $5.8 million ...Full story available on Benzinga.com.....»»

Category: earningsSource: benzingaSep 24th, 2021

S&P 500 ETF"s Best Day Since July: 6 Winning Stocks

On Sep 23, equities logged their best day since July. These stocks played a crucial role in boosting the S&P 500. On Sep 23, equities logged their best day since July, with the major indexes on their way to shake off their earlier weakness on Evergrande news. China real estate developer Evergrande agreed to settle interest payments on a domestic bond, while the Chinese central bank injected cash into the banking system, to eradicate global market fears of contagion from the debt-laden property developer and its default risks.Evergrande fears shook the markets lately on a potential of the Lehman-like crisis. However, equity investors now seem to overlook uncertainty over monetary and fiscal policy and ongoing debates in Washington over the debt ceiling. Buy-the-dip strategy also helped boost equities.Cyclical sectors outperformed as the Federal Reserve stressed on the economic progress. The Fed has also gave cues of an imminent QE taper. "It’s not a surprise to me that the Fed is moving forward with the tapering," Jeff Schulze, ClearBridge chief investment strategist, told Yahoo Finance. "If you think about the three-month moving average ... we're at about 740,000 jobs created per month. That is stronger than anything we've ever seen pre-COVID,” as quoted on Yahoo Finance (read: Fed Taper to Start in November? 7 ETFs to Buy).The benchmark U.S. 10-year yield touched 1.41% to reach its highest level since July on taper talks. Investors seemed okay with this rise in rates as growth stocks did not seem to have taken a hit on Sep 23. Economic progress probably has helped investors to keep patience and encouraged them to invest in the corporate strength.Against this backdrop, below we highlight a few stocks of the S&P 500 that played to a crucial role in boosting the index on Sep 23.Stocks in Focus  Amazon.com Inc. AMZN – Weight 3.95%; Up 1.06%Amazon.com is one of the largest e-commerce providers, with sprawling operations in North America, now spreading across the globe.NVIDIA Corporation NVDA – Weight 1.47%; Up 2.59%NVIDIA Corporation is the worldwide leader in visual computing technologies and the inventor of the graphic processing unit, or GPU. Over the years, the company’s focus has evolved from PC graphics to artificial intelligence (AI) based solutions that now support high performance computing (HPC), gaming and virtual reality (VR) platforms. The stock has a Zacks Rank #2 (Buy).JPMorgan Chase & Co. JPM – Weight 1.25%; Up 3.38%JPMorgan Chase & Co. is one of the biggest global banks with assets valued at $3.68 trillion and stockholders’ equity worth $286.4 billion as of Jun 30, 2021. With operations in more than 60 countries, the company (incorporated under Delaware law in 1968) is one of the largest financial service firms in the world. Being a bank, the stock is a beneficiary of the Fed taper cues as banks do fare better in a rising rate environment. The stock has a Zacks Rank #3 (Hold).Visa Inc. Class A V – Weight 1.00%; Up 2.50%Visa operates retail electronic payments network worldwide. The company went public in March 2008 via an initial public offering (IPO). The stock has a Zacks Rank #3.PayPal Holdings Inc (PYPL) – Weight 0.86%; Up 2.56%The Zacks Rank #3 PayPal has emerged as one of the largest online payment solutions providers on the back of its strong product portfolio and two-sided platform that enables it to offer smooth and secure transaction facility to both customers and merchants.salesforce.com inc. CRM – Weight 0.67%; Up 7.21%The Zacks Rank #3 company is the leading provider of on-demand Customer Relationship Management (CRM) software, which enables organizations to better manage critical operations, such as sales force automation, customer service and support, marketing automation, document management, analytics and custom application development. Time to Invest in Legal Marijuana If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027. After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%. You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.Today, Download Marijuana Moneymakers FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amazon.com, Inc. (AMZN): Free Stock Analysis Report JPMorgan Chase & Co. (JPM): Free Stock Analysis Report Visa Inc. (V): Free Stock Analysis Report salesforce.com, inc. (CRM): Free Stock Analysis Report NVIDIA Corporation (NVDA): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksSep 24th, 2021

Futures Slide Alongside Cryptocurrencies Amid China Crackdown

Futures Slide Alongside Cryptocurrencies Amid China Crackdown US futures and European stocks fell amid ongoing nerves over the Evergrande default, while cryptocurrency-linked stocks tumbled after the Chinese central bank said such transactions are illegal. Sovereign bond yields fluctuated after an earlier selloff fueled by the prospect of tighter monetary policy. At 745am ET, S&P 500 e-minis were down 19.5 points, or 0.43%, Nasdaq 100 e-minis were down 88.75 points, or 0.58% and Dow e-minis were down 112 points, or 0.33%. In the biggest overnight news, Evergrande offshore creditors remain in limbo and still haven't received their coupon payment effectively starting the 30-day grace period, while also in China, the State Planner issued a notice on the crackdown of cryptocurrency mining, will strictly prohibit financing for new crypto mining projects and strengthen energy consumption controls of new crypto mining projects. Subsequently, the PBoC issued a notice to further prevent and dispose of the risks from speculating on cryptocurrencies, to strengthen monitoring of risks from crypto trading and such activities are illegal. The news sent the crypto space tumbling as much as 8% while cryptocurrency-exposed stocks slumped in U.S. premarket trading. Marathon Digital (MARA) drops 6.5%, Bit Digital (BTBT) declines 4.7%, Riot Blockchain (RIOT) -5.9%, Coinbase -2.8%. Big banks including JPMorgan, Citigroup, Morgan Stanley and Bank of America Corp slipped about 0.5%, while oil majors Exxon Mobil and Chevron Corp were down 0.4% and 0.3%, respectively, in premarket trading.Mega-cap FAAMG tech giants fell between 0.5% and 0.6%. Nike shed 4.6% after the sportswear maker cut its fiscal 2022 sales expectations and warned of delays during the holiday shopping season. Several analysts lowered their price targets on the maker of sports apparel and sneakers after the company cut its FY revenue growth guidance to mid-single- digits. Here are some of the biggest U.S. movers today: Helbiz (HLBZ) falls 10% after the micromobility company filed with the SEC for the sale of as many as 11m shares by stockholders. Focus Universal (FCUV), an online marketing company that’s been a favorite of retail traders, surged 26% in premarket trading after the stock was cited on Stocktwits in recent days. Vail Resorts (MTN) falls 2.7% in postmarket trading after its full-year forecasts for Ebitda and net income missed at the midpoint. GlycoMimetics (GLYC) jumps 15% postmarket after announcing that efficacy and safety data from a Phase 1/2 study of uproleselan in patients with acute myeloid leukemia were published in the journal Blood on Sept. 16. VTV Therapeutics (VTVT) surges 30% after company says its HPP737 psoriasis treatment showed favorable safety and tolerability profile in a multiple ascending dose study. Fears about a sooner-than-expected tapering amid signs of stalling U.S. economic growth and concerns over a spillover from China Evergrande’s default had rattled investors in September, putting the benchmark S&P 500 index on course to snap a seven-month winning streak. Elaine Stokes, a portfolio manager at Loomis Sayles & Co., told Bloomberg Television, adding that “what they did is tell us that they feel really good about the economy.” While the bond selloff vindicated Treasury bears who argue yields are too low to reflect fundamentals, others see limits to how high they can go. “We’d expected bond yields to go higher, given the macro situation where growth is still very strong,” Sylvia Sheng, global multi-asset strategist with JPMorgan Asset Management, said on Bloomberg Television. “But we do stress that is a modest view, because we think that upside to yields is still limited from here given that central banks including the Fed are still buying bonds.” Still, Wall Street’s main indexes rallied in the past two session and are set for small weekly gains. European equities dipped at the open but trade off worst levels, with the Euro Stoxx 50 sliding as much as 1.1% before climbing off the lows. France's CAC underperformed at the margin. Retail, financial services are the weakest performers. EQT AB, Europe’s biggest listed private equity firm, fell as much as 8.1% after Sweden’s financial watchdog opened an investigation into suspected market abuse. Here are some of the other biggest European movers today: SMCP shares surge as much as 9.9%, advancing for a 9th session in 10, amid continued hopes the financial troubles of its top shareholder will ultimately lead to a sale TeamViewer climbs much as 4.2% after Bankhaus Metzler initiated coverage with a buy rating, citing the company’s above-market growth AstraZeneca gains as much as 3.6% after its Lynparza drug met the primary endpoint in a prostate cancer trial Darktrace drops as much as 9.2%, paring the stock’s rally over the past few weeks, as a technical pattern triggered a sell signal Adidas and Puma fall as much as 4% and 2.9%, respectively, after U.S. rival Nike’s “large cut” to FY sales guidance, which Jefferies said would “likely hurt” shares of European peers Earlier in the session, Asian stocks rose for a second day, led by rallies in Japan and Taiwan, following U.S. peers higher amid optimism over the Federal Reserve’s bullish economic outlook and fading concerns over widespread contagion from Evergrande. Stocks were muted in China and Hong Kong. India’s S&P BSE Sensex topped the 60,000 level for the first time on Friday on optimism that speedier vaccinations will improve demand for businesses in Asia’s third-largest economy. The MSCI Asia Pacific Index gained as much as 0.7%, with TSMC and Sony the biggest boosts. That trimmed the regional benchmark’s loss for the week to about 1%. Japan’s Nikkei 225 climbed 2.1%, reopening after a holiday, pushing its advance for September to 7.7%, the best among major global gauges. The Asian regional benchmark pared its gain as Hong Kong stocks fell sharply in late afternoon trading amid continued uncertainty, with Evergrande giving no sign of making an interest payment that was due Thursday. Among key upcoming events is the leadership election for Japan’s ruling party next week, which will likely determine the country’s next prime minister. “Investor concerns over the Evergrande issue have retreated a bit for now,” said Hajime Sakai, chief fund manager at Mito Securities Co. in Tokyo. “But investors will have to keep downside risk in the corner of their minds.” Indian stocks rose, pushing the Sensex above 60,000 for the first time ever. Key gauges fell in Singapore, Malaysia and Australia, while the Thai market was closed for a holiday. Treasuries are higher as U.S. trading day begins after rebounding from weekly lows reached during Asia session, adding to Thursday’s losses. The 10-year yield was down 1bp at ~1.42%, just above the 100-DMA breached on Thursday for the first time in three months; it climbed to 1.449% during Asia session, highest since July 6, and remains 5.2bp higher on the week, its fifth straight weekly increase. Several Fed speakers are slated, first since Wednesday’s FOMC commentary set forth a possible taper timeline.  Bunds and gilts recover off cheapest levels, curves bear steepening. USTs bull steepen, richening 1.5bps from the 10y point out. Peripheral spreads are wider. BTP spreads widen 2-3bps to Bunds. In FX, the Bloomberg Dollar Spot Index climbed back from a one-week low as concern about possible contagion from Evergrande added to buying of the greenback based on the Federal Reserve tapering timeline signaled on Wednesday. NZD, AUD and CAD sit at the bottom of the G-10 scoreboard. ZAR and TRY are the weakest in EM FX. The pound fell after its rally on Thursday as investors looked ahead to BOE Governor Andrew Bailey’s sPeech next week about a possible interest-rate hike. Traders are betting that in a contest to raise borrowing costs first, the Bank of England will be the runaway winner over the Federal Reserve. The New Zealand and Aussie dollars led declines among Group-of-10 peers. The euro was trading flat, with a week full of events failing “to generate any clear directional move,” said ING analysts Francesco Pesole and Chris Turner. German IFO sentiment indeces will “provide extra indications about the area’s sentiment as  businesses faced a combination of delta variant concerns and lingering supply disruptions”. The Norwegian krone is the best performing currency among G10 peers this week, with Thursday’s announcement from the Norges Bank offering support In commodities, crude futures hold a narrow range up around best levels for the week. WTI stalls near $73.40, Brent near $77.50. Spot gold extends Asia’s gains, adding $12 on the session to trade near $1,755/oz. Base metals are mixed, LME nickel and aluminum drop ~1%, LME tin outperforms with a 2.8% rally. Bitcoin dips after the PBOC says all crypto-related transactions are illegal. Looking to the day ahead now, we’ll hear from Fed Chair Powell, Vice Chair Clarida and the Fed’s Mester, Bowman, George and Bostic, as well as the ECB’s Lane and Elderson, and the BoE’s Tenreyro. Finally, a summit of the Quad Leaders will be held at the White House, including President Biden, and the Prime Ministers of Australia, India and Japan. Market Snapshot S&P 500 futures down 0.3% to 4,423.50 STOXX Europe 600 down 0.7% to 464.18 German 10Y yield fell 8.5 bps to -0.236% Euro little changed at $1.1737 MXAP up 0.4% to 201.25 MXAPJ down 0.5% to 643.20 Nikkei up 2.1% to 30,248.81 Topix up 2.3% to 2,090.75 Hang Seng Index down 1.3% to 24,192.16 Shanghai Composite down 0.8% to 3,613.07 Sensex up 0.2% to 60,031.83 Australia S&P/ASX 200 down 0.4% to 7,342.60 Kospi little changed at 3,125.24 Brent Futures up 0.4% to $77.57/bbl Gold spot up 0.7% to $1,755.38 U.S. Dollar Index little changed at 93.14 Top Overnight News from Bloomberg China Evergrande Group’s unusual silence about a dollar-bond interest payment that was due Thursday has put a focus on what might happen during a 30-day grace period. The Reserve Bank of Australia’s inflation target is increasingly out of step with international counterparts and fails to account for structural changes in the country’s economy over the past 30 years, Westpac Banking Corp.’s Bill Evans said. With central banks from Washington to London this week signaling more alarm over faster inflation, the ultra-stimulative path of the euro zone and some of its neighbors appears lonelier than ever. China’s central bank continued to pump liquidity into the financial system on Friday as policy makers sought to avoid contagion stemming from China Evergrande Group spreading to domestic markets. A more detailed look at global markets courtesy of Newsquawk Asian equity markets traded mixed with the region failing to fully sustain the impetus from the positive performance across global counterparts after the silence from Evergrande and lack of coupon payments for its offshore bonds, stirred uncertainty for the company. ASX 200 (-0.4%) was negative as underperformance in mining names and real estate overshadowed the advances in tech and resilience in financials from the higher yield environment. Nikkei 225 (+2.1%) was the biggest gainer overnight as it played catch up to the prior day’s recovery on return from the Autumnal Equinox holiday in Japan and with exporters cheering the recent risk-conducive currency flows, while KOSPI (-0.1%) was lacklustre amid the record daily COVID-19 infections and after North Korea deemed that it was premature to declare that the Korean War was over. Hang Seng (-1.2%) and Shanghai Comp. (-0.8%) were indecisive after further liquidity efforts by the PBoC were offset by concerns surrounding Evergrande after the Co. failed to make coupon payments due yesterday for offshore bonds but has a 30-day grace period with the Co. remaining quiet on the issue. Finally, 10yr JGBs were lower on spillover selling from global counterparts including the declines in T-notes as the US 10yr yield breached 1.40% for the first time since early-July with the pressure in bonds also stemming from across the Atlantic following a more hawkish BoE, while the presence of the BoJ in the market today for over JPY 1.3tln of government bonds with 1yr-10yr maturities did very little to spur prices. Top Asian News Rivals for Prime Minister Battle on Social Media: Japan Election Asian Stocks Rise for Second Day, Led by Gains in Japan, Taiwan Hong Kong Stocks Still Wagged by Evergrande Tail Hong Kong’s Hang Seng Tech Index Extends Decline to More Than 2% European equities (Stoxx 600 -0.9%) are trading on the back foot in the final trading session of the week amid further advances in global bond yields and a mixed APAC handover. Overnight, saw gains for the Nikkei 225 of 2.1% with the index aided by favourable currency flows, whilst Chinese markets lagged (Shanghai Comp. -0.8%, Hang Seng -1.6%) with further liquidity efforts by the PBoC offset by concerns surrounding Evergrande after the Co. failed to make coupon payments due yesterday for offshore bonds. As context, despite the losses in Europe today, the Stoxx 600 is still higher by some 1.2% on the week. Stateside, futures are also on a softer footing with the ES down by 0.4% ahead of a busy Fed speaker schedule. Back to Europe, sectors are lower across the board with Retail and Personal & Household Goods lagging peers. The former has been hampered by losses in Adidas (-3.0%) following after hours earnings from Nike (-4.2% pre-market) which saw the Co. cut its revenue guidance amid supply chain woes. AstraZeneca (+2.1%) sits at the top of the FTSE 100 after announcing that the Lynparza PROpel trial met its primary endpoint. Daimler’s (+0.1%) Mercedes-Benz has announced that it will take a 33% stake in a battery cell manufacturing JV with Total and Stellantis. EQT (-6.5%) sits at the foot of the Stoxx 600 after the Swedish FSA announced it will open an investigation into the Co. Top European News EQT Investigated by Sweden’s FSA Over Suspected Market Abuse Gazprom Says Claims of Gas Under-supply to Europe Are ‘Absurd’ German Sept. Ifo Business Confidence 98.8; Est. 99 German Business Index at Five-Month Low in Pre-Election Verdict In FX, the rot seems to have stopped for the Buck in terms of its sharp and marked fall from grace amidst post-FOMC reflection and re-positioning in the financial markets on Thursday. Indeed, the Dollar index has regained some poise to hover above the 93.000 level having recoiled from 93.526 to 92.977 over the course of yesterday’s hectic session that saw the DXY register a marginal new w-t-d high and low at either end of the spectrum. Pre-weekend short covering and consolidation may be giving the Greenback a lift, while the risk backdrop is also less upbeat ahead of a raft of Fed speakers flanking US new home sales data. Elsewhere, the Euro remains relatively sidelined and contained against the Buck with little independent inspiration from the latest German Ifo survey as the business climate deteriorated broadly in line with consensus and current conditions were worse than forecast, but business expectations were better than anticipated. Hence, Eur/Usd is still stuck in a rut and only briefly/fractionally outside 1.1750-00 parameters for the entire week, thus far, as hefty option expiry interest continues to keep the headline pair in check. However, there is significantly less support or gravitational pull at the round number today compared to Thursday as ‘only’ 1.3 bn rolls off vs 4.1 bn, and any upside breach could be capped by 1.1 bn between 1.1765-85. CAD/NZD/AUD - Some payback for the non-US Dollars following their revival, with the Loonie waning from 1.2650+ peaks ahead of Canadian budget balances, though still underpinned by crude as WTI hovers around Usd 73.50/brl and not far from decent option expiries (from 1.2655-50 and 1.2625-30 in 1.4 bn each). Similarly, the Kiwi has faded after climbing to within single digits of 0.7100 in wake of NZ trade data overnight revealing a much wider deficit as exports slowed and imports rose, while the Aussie loses grip of the 0.7300 handle and skirts 1.1 bn option expiries at 0.7275. CHF/GBP/JPY - The Franc is fairly flat and restrained following a dovish SNB policy review that left in lagging somewhat yesterday, with Usd/Chf and Eur/Chf straddling 0.9250 and 1.0850 respectively, in contrast to Sterling that is paring some hawkish BoE momentum, as Cable retreats to retest bids circa 1.3700 and Eur/Gbp bounces from sub-0.8550. Elsewhere, the Yen has not been able to fend off further downside through 110.00 even though Japanese participants have returned to the fray after the Autumn Equinox holiday and reports suggest some COVID-19 restrictions may be lifted in 13 prefectures on a trial basis. SCANDI/EM/PM/CRYPTO - A slight change in the pecking order in Scandi-land as the Nok loses some post-Norges Bank hike impetus and the Sek unwinds a bit of its underperformance, but EM currencies are bearing the brunt of the aforementioned downturn in risk sentiment and firmer Usd, with the Zar hit harder than other as Gold is clings to Usd 1750/oz and Try down to deeper post-CBRT rate cut lows after mixed manufacturing sentiment and cap u readings. Meanwhile, Bitcoin is being shackled by the latest Chinese crackdown on mining and efforts to limit risks from what it describes as unlawful speculative crypto currency trading. In commodities, WTI and Brent are set the conclude the week in the green with gains in excess of 2% for WTI at the time of writing; in-spite of the pressure seen in the complex on Monday and the first-half of Tuesday, where a sub USD 69.50/bbl low was printed. Fresh newsflow has, once again, been limited for the complex and continues to focus on the gas situation. More broadly, no update as of yet on the Evergrande interest payment and by all accounts we appear to have entered the 30-day grace period for this and, assuming catalysts remain slim, updates on this will may well dictate the state-of-play. Schedule wise, the session ahead eyes significant amounts of central bank commentary but from a crude perspective the weekly Baker Hughes rig count will draw attention. On the weather front, Storm Sam has been upgraded to a Hurricane and is expected to rapidly intensify but currently remains someway into the mid-Atlantic. Moving to metals, LME copper is pivoting the unchanged mark after a mixed APAC lead while attention is on Glencore’s CSA copper mine, which it has received an offer for; the site in 2020 produced circa. 46k/T of copper which is typically exported to Asia smelters. Elsewhere, spot gold and silver are firmer but have been very contained and remain well-within overnight ranges thus far. Which sees the yellow metal holding just above the USD 1750/oz mark after a brief foray below the level after the US-close. US Event Calendar 10am: Aug. New Home Sales MoM, est. 1.0%, prior 1.0% 10am: Aug. New Home Sales, est. 715,000, prior 708,000 Central Bank Speakers 8:45am: Fed’s Mester Discusses the Economic Outlook 10am: Powell, Clarida and Bowman Host Fed Listens Event 10:05am: Fed’s George Discusses Economic Outlook 12pm: Fed’s Bostic Discusses Equitable Community Development DB's Jim Reid concludes the overnight wrap WFH today is a bonus as it’s time for the annual ritual at home where the latest, sleekest, shiniest iPhone model arrives in the post and i sheepishly try to justify to my wife when I get home why I need an incremental upgrade. This year to save me from the Spanish Inquisition I’m going to intercept the courier and keep quiet. Problem is that such speed at intercepting the delivery will be logistically challenging as I remain on crutches (5 weeks to go) and can’t grip properly with my left hand due to an ongoing trapped nerve. I’m very glad I’m not a racehorse. Although hopefully I can be put out to pasture in front of the Ryder Cup this weekend. The big news of the last 24 hours has been a galloping global yield rise worthy of the finest thoroughbred. A hawkish Fed meeting, with the dots increasing and the end of QE potentially accelerated, didn’t quite have the ability to move markets but the global dam finally broke yesterday with Norway being the highest profile developed country to raise rates this cycle (expected), but more importantly a Bank of England meeting that saw the market reappraise rate hikes. Looking at the specific moves, yields on 10yr Treasuries were up +13.0bps to 1.430% in their biggest daily increase since 25 February, as both higher real rates (+7.9bps) and inflation breakevens (+4.9bps) drove the advance. US 10yr yields had been trading in a c.10bp range for the last month before breaking out higher, though they have been trending higher since dropping as far as 1.17% back in early-August. US 30yr yields rose +13.2bps, which was the biggest one day move in long dated yields since March 17 2020, which was at the onset of the pandemic and just days after the Fed announced it would be starting the current round of QE. The large selloff in US bonds saw the yield curve steepen and the long-end give back roughly half of the FOMC flattening from the day before. The 5y30y curve steepened 3.4bps for a two day move of -3.3bps. However the 2y10y curve steepened +10.5bps, completely reversing the prior day’s flattening (-4.2bps) and leaving the spread at 116bp, the steepest level since first week of July. 10yr gilt yields saw nearly as strong a move (+10.8bps) with those on shorter-dated 2yr gilts (+10.7bps) hitting their highest level (0.386%) since the pandemic began.That came on the back of the BoE’s latest policy decision, which pointed in a hawkish direction, building on the comment in the August statement that “some modest tightening of monetary policy over the forecast period is likely to be necessary” by saying that “some developments during the intervening period appear to have strengthened that case”. The statement pointed out that the rise in gas prices since August represented an upside risks to their inflation projections from next April, and the MPC’s vote also saw 2 members (up from 1 in August) vote to dial back QE. See DB’s Sanjay Raja’s revised rate hike forecasts here. We now expect a 15bps hike in February. The generalised move saw yields in other European countries rise as well, with those on 10yr bunds (+6.6bps), OATs (+6.5bps) and BTPs (+5.7bps) all seeing big moves higher with 10yr bunds seeing their biggest climb since late-February and back to early-July levels as -0.258%. The yield rise didn’t stop equity indices recovering further from Monday’s rout, with the S&P 500 up +1.21% as the index marked its best performance in over 2 months, and its best 2-day performance since May. Despite the mood at the end of the weekend, the S&P now starts Friday in positive territory for the week. The rally yesterday was led by cyclicals for a second straight day with higher commodity prices driving outsized gains for energy (+3.41%) and materials (+1.39%) stocks, and the aforementioned higher yields causing banks (+3.37%) and diversified financials (+2.35%) to outperform. The reopening trade was the other main beneficiary as airlines rose +2.99% and consumer services, which include hotel and cruiseline companies, gained +1.92%. In Europe, the STOXX 600 (+0.93%) witnessed a similarly strong performance, with index led by banks (+2.16%). As a testament to the breadth of yesterday’s rally, the travel and leisure sector (+0.04%) was the worst performing sector on this side of the Atlantic even while registering a small gain and lagging its US counterparts. Before we get onto some of yesterday’s other events, it’s worth noting that this is actually the last EMR before the German election on Sunday, which has long been signposted as one of the more interesting macro events on the 2021 calendar, the results of which will play a key role in not just domestic, but also EU policy. And with Chancellor Merkel stepping down after four terms in office, this means that the country will soon be under new management irrespective of who forms a government afterwards. It’s been a volatile campaign in many respects, with Chancellor Merkel’s CDU/CSU, the Greens and the centre-left SPD all having been in the lead at various points over the last six months. But for the last month Politico’s Poll of Polls has shown the SPD consistently ahead, with their tracker currently putting them on 25%, ahead of the CDU/CSU on 22% and the Greens on 16%. However the latest poll from Forschungsgruppe Wahlen yesterday suggested a tighter race with the SPD at 25, the CDU/CSU at 23% and the Greens at 16.5%. If the actual results are in line with the recent averages, it would certainly mark a sea change in German politics, as it would be the first time that the SPD have won the popular vote since the 2002 election. Furthermore, it would be the CDU/CSU’s worst ever result, and mark the first time in post-war Germany that the two main parties have failed to win a majority of the vote between them, which mirrors the erosion of the traditional big parties in the rest of continental Europe. For the Greens, 15% would be their best ever score, and exceed the 9% they got back in 2017 that left them in 6th place, but it would also be a disappointment relative to their high hopes back in the spring, when they were briefly polling in the mid-20s after Annalena Baerbock was selected as their Chancellor candidate. In terms of when to expect results, the polls close at 17:00 London time, with initial exit polls released immediately afterwards. However, unlike the UK, where a new majority government can immediately come to power the day after the election, the use of proportional representation in Germany means that it could potentially be weeks or months before a new government is formed. Indeed, after the last election in September 2017, it wasn’t until March 2018 that the new grand coalition between the CDU/CSU and the SPD took office, after attempts to reach a “Jamaica” coalition between the CDU/CSU, the FDP and the Greens was unsuccessful. In the meantime, the existing government will act as a caretaker administration. On the policy implications, it will of course depend on what sort of government is actually formed, but our research colleagues in Frankfurt have produced a comprehensive slidepack (link here) running through what the different parties want across a range of policies, and what the likely coalitions would mean for Germany. They also put out another note yesterday (link here) where they point out that there’s still much to play for, with the SPD’s lead inside the margin of error and with an unusually high share of yet undecided voters. Moving on to Asia and markets are mostly higher with the Nikkei (+2.04%), CSI (+0.53%) and India’s Nifty (+0.52%) up while the Hang Seng (-0.03%), Shanghai Comp (-0.07%) and Kospi (-0.10%) have all made small moves lower. Meanwhile, the Evergrande group missed its dollar bond coupon payment yesterday and so far there has been no communication from the group on this. They have a 30-day grace period to make the payment before any event of default can be declared. This follows instructions from China’s Financial regulators yesterday in which they urged the group to take all measures possible to avoid a near-term default on dollar bonds while focusing on completing unfinished properties and repaying individual investors. Yields on Australia and New Zealand’s 10y sovereign bonds are up +14.5bps and +11.3bps respectively this morning after yesterday’s move from their western counterparts. Yields on 10y USTs are also up a further +1.1bps to 1.443%. Elsewhere, futures on the S&P 500 are up +0.04% while those on the Stoxx 50 are down -0.10%. In terms of overnight data, Japan’s August CPI printed at -0.4% yoy (vs. -0.3% yoy expected) while core was unchanged in line with expectations. We also received Japan’s flash PMIs with the services reading at 47.4 (vs. 42.9 last month) while the manufacturing reading came in at 51.2 (vs. 52.7 last month). In pandemic related news, Jiji reported that Japan is planning to conduct trials of easing Covid restrictions, with 13 prefectures indicating they’d like to participate. This is likely contributing to the outperformance of the Nikkei this morning. Back to yesterday now, and one of the main highlights came from the flash PMIs, which showed a continued deceleration in growth momentum across Europe and the US, and also underwhelmed relative to expectations. Running through the headline numbers, the Euro Area composite PMI fell to 56.1 (vs. 58.5 expected), which is the lowest figure since April, as both the manufacturing (58.7 vs 60.3 expected) and services (56.3 vs. 58.5 expected) came in beneath expectations. Over in the US, the composite PMI fell to 54.5 in its 4th consecutive decline, as the index hit its lowest level in a year, while the UK’s composite PMI at 54.1 (vs. 54.6 expected) was the lowest since February when the country was still in a nationwide lockdown. Risk assets seemed unperturbed by the readings, and commodities actually took another leg higher as they rebounded from their losses at the start of the week. The Bloomberg Commodity Spot index rose +1.12% as Brent crude oil (+1.39%) closed at $77.25/bbl, which marked its highest closing level since late 2018, while WTI (+1.07%) rose to $73.30/bbl, so still a bit beneath its recent peak in July. However that is a decent rebound of roughly $11/bbl since its recent low just over a month ago. Elsewhere, gold (-1.44%) took a knock amidst the sharp move higher in yields, while European natural gas prices subsidised for a third day running, with futures now down -8.5% from their intraday peak on Tuesday, although they’re still up by +71.3% since the start of August. US negotiations regarding the upcoming funding bill and raising the debt ceiling are ongoing, with House Speaker Pelosi saying that the former, also called a continuing resolution, will pass “both houses by September 30,” and fund the government through the first part of the fiscal year, starting October 1. Treasury Secretary Yellen has said the US will likely breach the debt ceiling sometime in the next month if Congress does not increase the level, and because Republicans are unwilling to vote to raise the ceiling, Democrats will have to use the once-a-fiscal-year tool of budget reconciliation to do so. However Democrats, are also using that process for the $3.5 trillion dollar economic plan that makes up the bulk of the Biden agenda, and have not been able to get full party support yet. During a joint press conference with Speaker Pelosi, Senate Majority Leader Schumer said that Democrats have a “framework” to pay for the Biden Economic agenda, which would imply that the broad outline of a deal was reached between the House, Senate and the White House. However, no specifics were mentioned yesterday. With Democrats looking to vote on the bipartisan infrastructure bill early next week, negotiations today and this weekend on the potential reconciliation package will be vital. Looking at yesterday’s other data, the weekly initial jobless claims from the US for the week through September 18 unexpectedly rose to 351k (vs. 320k expected), which is the second week running they’ve come in above expectations. Separately, the Chicago Fed’s national activity index fell to 0.29 in August (vs. 0.50 expected), and the Kansas City Fed’s manufacturing activity index also fell more than expected to 22 in September (vs. 25 expected). To the day ahead now, and data highlights include the Ifo’s business climate indicator from Germany for September, along with Italian consumer confidence for September and US new home sales for August. From central banks, we’ll hear from Fed Chair Powell, Vice Chair Clarida and the Fed’s Mester, Bowman, George and Bostic, as well as the ECB’s Lane and Elderson, and the BoE’s Tenreyro. Finally, a summit of the Quad Leaders will be held at the White House, including President Biden, and the Prime Ministers of Australia, India and Japan. Tyler Durden Fri, 09/24/2021 - 08:12.....»»

Category: blogSource: zerohedgeSep 24th, 2021

Citi (C) and Snowflake Partner to Revamp Post-Trade Data Flows

Citi (C) and Snowflake (SNOW) to jointly integrate their data platforms in a bid to revamp the post-trade data flows that will help deliver faster, complete and cost-effective client data. In order to help the bank trim costs and streamline its post-trade processes, Citigroup C recently entered into a strategic partnership with Snowflake SNOW to re-assess and reform the processes across financial services transactions. Snowflake’s Financial Services Data Cloud aids firms to boost their top-line growth and steer innovation while alleviating any risk.A mammoth host of players across markets have to reconcile transactions in their ledgers any time a trade activity occurs. Per a Bloomberg article, Fiona Horsewill, the head of data for Citi’s securities-services business, believes that with this tie-up, Citi will be well poised to provide a real-time record of that data to all parties in a transaction.In Snowflake’s Data Cloud provider-agnostic cloud environment, this partnership will mobilize Snowflake’s robust, secured data sharing as well as multi-party permissioning faculties with Citi’s wide market expertise. Moreover, it will leverage on Citi's leading proprietary custody network footprint traversing more than 60 markets and global markets franchise.Snowflake’s software is used for warehousing data in the cloud. It has been working with companies which are renovating their corporate applications and networks. Citi also has a verified track record in conceiving and renovating industry processes, in partnership with its Innovation Lab network and D10X programs. It had also worked out an industry problem connected to proxy voting and shared this with the industry via Proxymity.Chris Cox, global head of Data and Digitization for Citi Securities Services, said, “The vision for this initiative is to provide a similar outcome and deliver the next generation of securities services to our clients and their counterparts. Integrating Snowflake with Citi’s VelocitySM Clarity data platform can help to deliver faster, more complete client data—adding the Snowflake channel option to existing real-time APIs and visualizations—plus opening the door to some other interesting possibilities.”The collaboration will offer a far-out solution by controlling data models and ensuring seamless end-to-end transaction data flow across a business, in order to fulfill the diverse needs of global clients.Okan Pekin, global head of Citi Securities Services, noted, “Clearly, if we were to start afresh, we would not design market transaction data workflows in the way they function today. In partnership with Snowflake, we are striving to provide solutions to the challenge of multiple records across multiple systems and the associated costs and data reconciliation consequences that hinder our clients and the industry today.”Costs linked to the post-trade process have flared up in recent years alongside the higher trading volumes. Hence, this tie-up will help reduce friction in the post-trade data process, curb costs and provide data in as near real-time as possible.Shares of this Zacks Rank #3 (Hold) company have depreciated 2.6% over the past six months, against the industry’s rally of 4.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Image Source: Zacks Investment ResearchBanks have been fortifying their digital capabilities as the demand for the same has been rising amid the coronavirus pandemic. Global banks such as HSBC Holdings HSBC, JPMorgan JPM and Bank of America are investing heavily in technology upgrades to enhance digital experience for customers. More Stock News: This Is Bigger than the iPhone! It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.Click here for the 4 trades >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report JPMorgan Chase & Co. (JPM): Free Stock Analysis Report Citigroup Inc. (C): Free Stock Analysis Report HSBC Holdings plc (HSBC): Free Stock Analysis Report Snowflake Inc. (SNOW): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksSep 23rd, 2021

Make the Most of Soaring Natural Gas Prices with These 5 Plays

Soaring energy prices and cheap valuations make this group attractive. Natural gas prices have been rising this year. The reason, according to the U.S. Energy Information Administration (EIA) is a warmer-than-usual summer that boosted electricity consumption for air conditioning, increased liquid natural gas (LNG) exports and flat production, which in combination led to a lower inventory build for the winter. The fact that hurricane Ida disrupted production in August also didn’t help.The other contributing factor was that natural gas prices typically rise in times of economic expansion, because of its use in the commercial sector, as well as processing in several industrial segments like chemicals, fertilizers, paper and glass. And we know how rapidly the economy has turned around.It’s now expected that prices will remain elevated through the winter because of the low inventories and increased demand from consumer, commercial and industrial users. And that is despite electric power consumption dropping an estimated 8.3% this year as the sector shifts some consumption to coal (the usual fallback when prices continue to rise). The electric power sector is the largest end-use case for natural gas, and it’s highly sensitive to prices. Less elastic demand comes from things like lease and plant fuel, pipeline and distribution use, and vehicle use and these segments are likely to see steady growth through 2022.The EIA estimates that despite increased production, natural gas inventories will be 5% below the 5-year average at the end of the 2021 injection season (October-end). Next year, demand from electricity suppliers will fall further, as additional clean energy sources come online.Important NumbersHenry Hub spot prices in August were $1.77 per million British thermal units (MMBtu) higher than in August 2020.U.S. consumption of natural gas will average 82.5 billion cubic feet per day (Bcf/d) in 2021, down 0.9% from 2020, remaining more or less steady at 82.6 Bcf/d in 2022.Residential and commercial natural gas consumption combined will rise by 1.2 Bcf/d, industrial consumption will rise by 0.6 Bcf/d and the electric power sector’s consumption will drop by 2.7 Bcf/d, or 8.3% in 2021.Dry natural gas production will average 92.7 Bcf/d in the U.S. during 2H21—up from 91.7 Bcf/d in 1H21—and then rise to 95.4 Bcf/d in 2022.U.S. natural gas inventories ended August 2021 at about 2.9 trillion cubic feet (Tcf); inventories will end the 2021 injection season (end of October) at almost 3.6 Tcf, which would be 5% below the five-year average.LNG ExportsSince the U.S. is more or less replete in natural gas resource, the domestic market is well-developed with consumption balancing production more often than not, leading to low and steady prices. But the last few years have seen increased recognition across the world of LNG as a clean fuel and countries like China have made it part of their clean energy strategy. The high demand in Europe and Asia has sent global prices soaring, which in turn has encouraged U.S. manufacturers to export. The expansion of the domestic LNG market is changing the operating dynamics with the potential for prices to rise and stay higher in the future (because of increased international demand).Most players are involved in both natural gas and crude operations, although there’s an increased focus on natural gas of late.Let’s consider a few cases-Cheniere Energy, Inc. LNGHouston, TX-based Cheniere Energy is primarily engaged in businesses related to liquefied natural gas (or LNG) through its two business segments: LNG terminal and LNG and natural gas marketing. The company, through its controlling interest in Cheniere Energy Partners L.P., owns and operates the Sabine Pass LNG terminal in Louisiana – North America’s first large-scale liquefied gas export facility. Furthermore, Cheniere Energy owns and operates the 94-mile Creole Trail Pipeline – an interconnect between the Sabine Pass receiving terminal and the downstream markets – through its subsidiary.Cheniere Energy intends to construct up to six trains at Sabine Pass with each train expected to have a capacity of about 4.5 million tons per annum. While Trains 1, 2, 3 and 4 are functional; Train 5 is undergoing commissioning. Train 6 is being commercialized and has secured the necessary regulatory approvals.Cheniere Energy Partners is also developing a liquefaction and export terminal in Corpus Christi, TX. Train 1 commissioning is complete, Train 2 is under construction and Train 3 is commercialised with necessary approvals in place. The facility came online in 2019. Cheniere Energy intends to develop seven midscale liquefaction trains adjacent to the Corpus Christi Liquefaction facility (CCL). The company has initiated the regulatory approval process. The total production capacities for these trains are expected to be approximately 9.5 Mtpa.Additionally, Cheniere Energy is involved in LNG and natural gas marketing activities through its subsidiary, Cheniere Marketing LLC.Global LNG demand is likely to continue growing for the next few years. Cheniere Energy, the U.S.’s only listed LNG export pure play, foresees the fundamentals of LNG to be favorable in the long run, considering the secular shift to the cleaner burning fuel for power generation worldwide and in the Asia-Pacific region in particular. While the increasing demand for gas in the European power sector will be a key factor driving near-term LNG supply, longer-term consumption is set to come from Asian importers like China, India, South Korea and Pakistan.Being in the expansion phase of a capital-intensive business isn’t easy and the company has acquired a significant amount of debt. At the same time, its long-term contracts ensure steady cash flow and provide excellent visibility into the future.It’s therefore particularly encouraging that Cheniere’s expected earnings growth of 976.5% this year and 119.7% next year are significantly higher than its expected revenue growth of 46.4% and 13.6%. After a correction 30 days ago, its estimates are again on the rise.The shares carry a Zacks Rank #2 (Buy) and at 16.1X P/E, they’re trading below their median level over the past year. Definitely worth considering.Range Resources Corp. RRCBased in Fort Worth, TX, Range Resources is an independent oil and gas company engaged in the exploration, development and acquisition of oil and gas properties, primarily in the Appalachian Basin and North Louisiana. It is among the top 10 natural gas producers in the U.S. and is among the top NGL producers in the domestic market.The Appalachian Basin incorporates prolific acreages in Marcellus, Utica and Upper Devonian shale formations. In the Marcellus formation of the basin, it has a multi-decade inventory of premium drilling locations. Of the 3,100 undrilled wells in the region, 2,600 wells are liquids-rich and the rest have a natural gas predominance. Following the merger with Memorial Resource Development Corporation a few years back, Range Resources created a core acreage position in North Louisiana comprising 140,000 net acers with multiple formations of productive oil and natural gas.The company primarily sells its produced natural gas to midstream firms, utilities, marketing companies and industrial users. It also sells natural gas liquids (NGLs) and crude oil.As of Dec 31, 2020, total proved reserves were 17.2 trillion cubic feet equivalent (Tcfe), almost flat year over year. Around 95% of the company’s total proved reserves are located in the Marcellus region. Of the total proved reserves, roughly 57% was developed.Despite its considerable liquid resources, the company has been focusing on natural gas production because of growing global demand for clean energy. In 2020, its total production averaged 2.23 million cubic feet equivalent per day, of which 69.4% was natural gas. A similar trend is seen this year.Range Resources’ revenue is expected to grow 38.9% in 2021 and 3.6% in 2022. Earnings are expected to increase 2000% and 45.5%, respectively in the two years. Estimates for both years have been rising steadily: the 2021 estimate increased 47.4% in the last 90 days while the 2022 estimate increased 93.0%.The shares carry a Zacks Rank #1 (Strong Buy). At 8.7X P/E, they’re trading below their median level over the past year, making them really cheap at these levels.Continental Resources, Inc. CLROklahoma City, OK-based Continental Resources is an explorer and producer of oil and natural gas. The company operates premium resources in the North Dakota Bakken and Montana Bakken (among the country’s largest onshore oilfields) in northern U.S., the SCOOP and STACK plays of Oklahoma in southern U.S. and undeveloped leasehold acreage in eastern U.S. It also has strategic water assets in Bakken and Oklahoma.Given its presence in prolific regions, the company expects oil equivalent production growth of 8-10% CAGR from 2019 to 2023 which is expected to translate to average annual free cash flow of $3.5-$4 billion over the five-year period.At the end of 2020, the company’s estimated proved reserves were 1,103.8 MMBoe. During 2020, the company produced 300,090 barrels of oil equivalent per day (Boe/d), lower than 340,395 Boe/d in the year-ago quarter. Of the total production, oil accounted for nearly 58.2%.The company’s 2021 revenue and earnings are currently expected to grow 101.9% and 436.8%, respectively. While analysts still expect 2022 growth to be negative, estimates for both years continue to increase substantially (from $2.35 to $3.94 in 2021 and from $1.97 to $3.68 in 2022). The stronger pricing this year is clearly driving the numbers.The shares of this Zacks Rank #1 company are currently trading at a P/S of 2.99X, which is between their median and high values over the past year, although much lower than the S&P 500. While not cheap, they can’t be considered expensive either.Goodrich Petroleum Corp. GDPHouston, Texas-based Goodrich Petroleum is an exploration and production company. It primarily holds interests in the Haynesville Shale Trend in northwest Louisiana and East Texas; Tuscaloosa Marine Shale Trend located in southwest Mississippi and southeast Louisiana; and the Eagle Ford Shale Trend in South Texas. The company owns interests in 189 producing oil and natural gas wells located in 37 fields in six states of the United States.As of December 31, 2020, it had estimated proved reserves of approximately 543 billion cubic feet equivalent, which included 540 billion cubic feet of natural gas and 0.5 million barrels of crude oil or other liquid hydrocarbons of oil and condensate.The company’s revenues are expected to grow 60.5% this year and another 22.4% in the next. Its earnings are expected to grow 1676.2% this year followed by 25.3% growth in the next. Estimates for both years are galloping ahead. In the past 90 days, they’ve gone from $2.17 to 3.73 for 2021 and from 2.74 to 4.67 for 2022.Shares of this Zacks Rank #1 stock currently trade at 4.9X P/E, which is below their median level over the past year, and of course much lower than the S&P. They’re a steal at these levels.Magnolia Oil & Gas Corp. MGYMagnolia Oil & Gas is an independent upstream operator engaged in the exploration, development and production of natural gas, crude oil and natural gas liquids. Headquartered in Houston, TX, the firm is focused on the high-quality Eagle Ford Shale and Austin Chalk formations in South Texas.In South Texas, Magnolia’s position consists of more than 460,000 net acres, of which around 23,500 net acres are located in the highly productive Karnes County and nearly 440,000 net acres in the re-emerging Giddings Field.At Dec 31, 2020, Magnolia's total estimated proved reserves were 49.3 million barrels ((MMBbls) of oil, 28.5 MMBbls of natural gas liquids (“NGL”) and 207.6 billion cubic feet (Bcf) of natural gas, totaling 112.3 million barrels of oil-equivalent (MMboe) — 69% liquids, 76% developed.The company focuses on growth through a combination of acquisitions and active drilling. Since its inception in 2018, Magnolia has spent around 60% of operating cash flow on capital expenditures, 26% on acquisitions, 8% on stock buybacks, while preserving the remaining 6% as cash. In particular, Magnolia is focused on returning significant cash to its shareholders: it aims to repurchase 1% of its total scrips outstanding each quarter and introduce a semi-annual cash dividend in 2021.Given the COVID-related disruption in 2020, it’s understandable that revenue and earnings are expected to jump 88.7% and 10050% this year. But the 6.7% revenue growth and flattish earnings slated for the following year are particularly encouraging.The Zacks Rank #1 shares are trading cheap at 8.23X earnings (below median level of 12.09X over the past year). One-Month Price PerformanceImage Source: Zacks Investment Research More Stock News: This Is Bigger than the iPhone! It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.Click here for the 4 trades >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Range Resources Corporation (RRC): Free Stock Analysis Report Cheniere Energy, Inc. (LNG): Free Stock Analysis Report Continental Resources, Inc. (CLR): Free Stock Analysis Report Goodrich Petroleum Corporation (GDP): Free Stock Analysis Report Magnolia Oil & Gas Corp (MGY): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksSep 23rd, 2021

Ready to invest in Bitcoin? Here are 4 steps to get started

Here's everything you need to know about how to invest in bitcoin, from choosing an exchange and crypto wallet, to picking the right trading strategy. There are a variety of ways to invest in bitcoin, even if you aren't a professional day trader or regularly play the currency markets. Alyssa Powell/Insider Table of Contents: Masthead Sticky Bitcoin investing involves choosing an exchange, verifying your identity, and withdrawing to a wallet. Investing in bitcoin is risky since it's a volatile and speculative asset. Experts recommend using a buy-and-hold strategy when buying bitcoin, in order to average out rises and falls. Visit Insider's Investing Reference library for more stories. More than a decade into its existence, Bitcoin doesn't seem to be going away. The cryptocurrency has attracted good and bad headlines as it's worked its way through multiple peaks over the years, and despite a reputation for volatility, it continues to attract new investors with its promise of market-beating returns.Here's what to know about investing in Bitcoin.What to know about Bitcoin Bitcoin is a cryptocurrency. This means it's a form of electronic money that secures and validates transactions via the use of cryptography. In Bitcoin's case, people and organizations known as "miners" use computing hardware to calculate a code - known as a "hash" - that encrypts the data contained in transactions. This data is collected into "blocks," which are linked together in a blockchain that cannot, in theory, be changed once written.On an economic level, Bitcoin's creator - the pseudonymous Satoshi Nakamoto - created it in 2008 as a form of "sound money," akin to digital gold."What makes Bitcoin so special is that it has a finite supply of 21 million coins, with only a couple million left to be mined," explains Edward Moya, chief market strategist at OANDA's MarketPulse. "Simple supply and demand for Bitcoin is the main reason why prices have skyrocketed over the past year."Despite having a fixed maximum supply, Bitcoin has shown remarkable volatility throughout most of its life with major fluctuations in its price.Such swings make Bitcoin a highly speculative asset, one that should be considered only by traders willing to stomach a fair amount of risk. That said, at least some analysts suspect that its volatility will gradually decline over time, as its market grows and reduces its destabilizing reliance on leverage.Step 1: Choose a crypto exchange For most people, the best place to buy Bitcoin is on a crypto exchange. These are online platforms dedicated to facilitating trades in cryptocurrency, usually by offering trading pairs (e.g., USD to Bitcoin) and usually by matching buyers with sellers.In the US, the leading crypto exchange by volume and customer base is Coinbase. That said, other reputable - and regulated - crypto-exchanges include Kraken, Gemini, eToro, and Crypto.com.More inexperienced traders may wish to try a more general trading platform such as Robinhood. These have the benefit of being more user-friendly than the average crypto exchange, although their major downside is that many don't let users withdraw their bitcoin.Quick tip: New investors should check the fees charged by exchanges, since these can vary quite widely. They should also check for the minimum account balance required by their chosen platform, since certain exchanges impose a minimum. Others also set minimums for account deposits via bank transfer.Step 2: Choose a payment methodExchanges also vary in terms of the payment methods they support. Most major platforms do offer the option of linking your bank account for wire and ACH transfers, as well as the option of linking a debit card. Some also let you pay via PayPal, with Coinbase also supporting Apple Pay.Quick tip: Most bank transfer deposit options incur no fees. Nonetheless, certain special services (e.g., FedWire via Silvergate or Synapse) may require a small charge (e.g., $1 or $5), while using PayPal to deposit money into your exchange incurs a 2.5% charge with Coinbase, for instance.Regardless of the option you choose, you will have to verify your identity when first signing up for an account and registering a payment method. In the US, you're usually required to submit a scan of a state-issued ID, such as a driver's license or identification card.Depending on where you are and on your chosen platform, you may also be required to provide scans of additional documentation (such as your passport), as well as being asked to submit a proof of address.Step 3: Place your order Once you're verified and have deposited cash into your account, you can then begin buying Bitcoin. This process varies according to the exchange you use, with some exchanges offering a process that simply involves clicking a Buy or Sell button and then specifying how much Bitcoin you want to buy (or sell).In general, most crypto exchanges offer at least three basic order types:Market order: the option to choose if you simply want to buy Bitcoin at its current price. This type of order is usually completed in a matter of seconds, depending on the time of day.Stop order: an order where you specify the price at which you will buy or sell Bitcoin. This type is good if you want to make sure you sell Bitcoin before it falls too sharply. This type of order can take some time to execute, depending on how quickly the market moves.Limit order: instructs the exchange to execute a buy or sell order at a specific price or better. In contrast to stop orders, limit orders are visible to the market and can take longer to fill.Again, executing any one of these options usually involves clicking a Buy, Trade, or New order button on an exchange's home screen. You'll then be able to choose from the above three (and more advanced) options, before clicking a Submit button or something equivalent.Quick tip: All exchanges will let you buy a fraction of a bitcoin (BTC). So while the price of 1 BTC may seem prohibitively expensive right now, you will be able to choose to buy 0.1 BTC, 0.01 BTC or whatever else you type into the exchange's interface.How to buy Bitcoin with PayPalPayPal has enabled its US-based customers to buy Bitcoin (and other cryptocurrencies) since October 2020. But before you can purchase Bitcoin, you'll have to agree to their terms and conditions and then set up a PayPal Balance account first. From the home screen, click the button that looks like a bar graph. Jasmine Suarez/Insider Click Bitcoin. PayPal also offers the option to buy Ethereum, Litecoin, and Bitcoin Cash. Jasmine Suarez/Insider Scroll down and select how much you'd like to purchase. Then click Buy. PayPal provides preset amounts of Bitcoin you can purchase. Jasmine Suarez/Insider Quick tip: When you press the Buy button for the first time, you'll have to prove your identity (if you haven't done so on PayPal already). This involves providing your name, physical address, date of birth, and taxpayer identification number, and may also include submitting a copy of your ID and showing proof of address.Step 4: Store your crypto in a safe place While bigger exchanges are becoming safer, hacks and fraud remain a big problem for the industry. This is why investors with significant sums in Bitcoin are advised to consider storing their cryptocurrency themselves."Experienced traders that are very good with cybersecurity might prefer to own their wallets, as this gives you the ability to move your cryptocurrencies whenever you want to and not be subject to an exchange. The saying 'Not your keys, not your coins' was popular last year, as many exchanges got hacked or shut down," says Moya.This means transferring your Bitcoin from the exchange you use to your own cryptocurrency wallet. Such wallets come in two forms:Cold wallets: also known as hardware wallets, these are small devices that store your Bitcoin address' private key, which is necessary to transfer Bitcoin out of the address. They do not connect to the internet and are therefore considered safer than online, software-based alternatives.Hot wallets: also known as software wallets, these are apps that can be used through your phone, desktop computer, or web browser. They also store the private key of your Bitcoin address, but because they do connect to the internet, they aren't considered quite as safe as hardware/cold wallets.Software wallets aren't quite as secure as hardware wallets, but the leading varieties do still offer a range of security features, such as two-factor authentication and compatibility with hardware wallets.Selling bitcoin While many traders turn to Bitcoin in the hope of making big money fast, pretty much every analyst advocates a long-term, buy-and-hold strategy. This is largely because holding for a longer period of time tends to average out gains and losses, providing a greater probability of a significant positive return by the time you sell your Bitcoin."In my opinion, it is better to buy and hold, perhaps allocating a small portion of your portfolio to cryptocurrencies, focusing on the ones typically held by institutional investors, such as Bitcoin and Ethereum at the moment," says Nikolaos Panigirtzoglou, an analyst at JPMorgan Chase & Co.Likewise, many analysts also recommend adopting a dollar-cost-averaging (DCA) strategy, largely because this is another way of averaging out peaks and troughs."The best strategy for newcomers would be to [trade] Bitcoin on the DCA approach [...] you'll just buy a tiny bit on a monthly or weekly basis, not looking at the price movements at all," says Michaël van de Poppe, the CEO and founder of cryptocurrency consultancy, Eight.However, Moya warns that even with a long-term hold strategy, new traders are generally advised to enter the world of Bitcoin investing with the mindset that they could lose most of their money. "A new investor should only apply a very low, single-digit percentage of their trading portfolio to cryptocurrencies. Despite the many bullish calls for Bitcoin or Ethereum, massive plunges have happened in minutes. New investors may want to consider buying and holding a basket of cryptocurrencies, with an approach of scaling into positions," he says.A longer-term approach is also beneficial from a tax perspective, since Bitcoin is classified as property in the US, and therefore liable to capital gains tax when sold. Quick tip: You'll have to pay capital gains tax if you sell bitcoin after holding it for more than one year. But if you hold for less than a year, your gains are taxed as ordinary income. Investors with an annual income of $40,000 or less pay no capital gains tax on Bitcoin profits, whereas those in the next bracket pay 15%.The financial takeawayBitcoin is an interesting and exciting technological innovation, representing a form of decentralized electronic money that doesn't require a central authority (such as the Federal Reserve) to operate. It's also exciting from an investment perspective, with its high annual returns (in most years) making it one of the best-performing assets of the past decade, even if its volatility means it has suffered more than a few dramatic falls.While investing in Bitcoin may seem complicated, starting off is as simple as picking a reputable exchange and setting up an account. Once you've verified your identity and deposited some money, you're then good to go, with most exchanges offering a range of order types in addition to the ability to simply buy Bitcoin.When you've acquired a significant sum of Bitcoin, most experts recommend withdrawing it to your own cold (i.e., hardware) wallet. They also recommend a buy-and-hold strategy, so that you can iron out market dips and also avoid having your profits taxed as ordinary income.A bitcoin IRA lets you profit from the cryptocurrency's potential gains in a tax-advantaged wayAltcoins are the alternative digital currencies to bitcoin - here's what they are and how they workWhat is Ethereum? What to know before investingWhat to know about non-fungible tokens (NFTs) - unique digital assets built on blockchain technologyRead the original article on Business Insider.....»»

Category: topSource: businessinsiderSep 23rd, 2021

10 hotels in South Florida with gorgeous rooftop pools and lively bars

These are the best hotels with rooftop pools and restaurants in South Florida, including Miami, Palm Beach, Fort Lauderdale, and more. When you buy through our links, Insider may earn an affiliate commission. Learn more. Tripadvisor South Florida's warm, tropical climate makes it a top vacation destination. From West Palm Beach to Miami, South Florida hotels have incredible rooftops to soak up the sun. Some hotel rooftop bars, restaurants, and pools are open to the public in addition to guests. Table of Contents: Masthead StickySouth Florida is known for its dazzling beaches but also its lively nightlife. And because the region stays warm when the sun goes down, many hotels have in-demand rooftops with outdoor restaurants, bars, and pools that draw visitors day and night.Few things top an afternoon laying out by a pool perched in the sky, enjoying happy hour with views of the Atlantic Ocean in the background, or watching a sunset while savoring a delicious meal. Living in South Florida has given me the opportunity to frequent some of the best hotels, and the following list of hotels all have incredible rooftops that make it easy to savor all the best parts of visiting the Sunshine State.Browse all the best hotels with rooftop pools and restaurants below, or jump directly to a specific area here:The best hotel rooftops in South FloridaFAQ: South Florida hotelsHow we selected the best South Florida hotels with rooftopsMore of the best hotels in FloridaThese are the best hotel rooftops with pools and restaurants in South Florida, sorted by price from low to high. Courtyard Fort Lauderdale Downtown The Easton rooftop combines a pool, restaurant, bar, and nightclub. Marriott Book Courtyard Fort Lauderdale DowntownCategory: Budget Town: Fort Lauderdale Typical starting/peak prices: $152/$365Best for: Friends, solo travelers, Marriott loyalists On-site amenities: 24-hour fitness center, library, business center, pet-friendly rooms, pool, restaurant, barPros: The rooms are well priced, and the rooftop bar is a hot nightlife destination with a DJ and bottle service on the weekends. Cons: On the flip side, the rooftop bar can get crowded, and noise can carry into the guest rooms late into the night.The Courtyard Fort Lauderdale Downtown recently opened in March 2021, nestled in the hip Fort Lauderdale Arts District, just a few miles from Fort Lauderdale Beach and Las Olas Boulevard, the main dining and entertainment strip. Rooms start under $200, which is well priced for a new hotel in such a great location. Most of the 137 guest rooms and suites have views of the Fort Lauderdale city skyline and are outfitted with modern wallpaper, soft carpeting, orange leather armchairs, and sofa beds in some rooms. The hotel is also home to The Easton, a ninth-story rooftop with a restaurant, bar, pool, and plush outdoor seating.  The Easton fills up quickly, especially during weekday Golden Happy Hour, and on the weekends, the rooftop transforms into a nightclub from 10 p.m. to 3 a.m. with visitors lining up for live music and bottle service. COVID-19 procedures are available here. Canopy by Hilton West Palm Beach Downtown Ban.ter Treehouse, the 13th-floor rooftop bar and restaurant has seating spread around a sparkling infinity pool. Tripadvisor Book Canopy by Hilton West Palm Beach DowntownCategory: Mid-rangeTown: West Palm Beach Typical starting/peak prices: $174/$423 Best for: Friends, Hilton loyalists, travelers with pets  On-site amenities: Pet-friendly rooms, complimentary evening wine and beer tastings, complimentary bicycle rentals, restaurant, bar, poolPros: The hotel is close to the airport in a great central location for exploring trendy downtown West Palm Beach. Cons: While the views on the rooftop are great, the seating is limited.Canopy by Hilton West Palm Beach opened in 2020 and is the only Hilton Canopy in Florida, a new boutique lifestyle concept from the brand. Canopy hotels pride themselves on creating a locally-driven by connecting guests to events, music, and restaurants in the surrounding area. The 150 room hotel is less than three miles from Palm Beach International Airport and about a mile from the beach. Rooms are brand new and have been outfitted with gray bedding, oversized artwork, and a dedicated workspace. Standard rooms are spacious at almost 400 square feet, and Deluxe Rooms have city and ocean views. Ban.ter, the lobby restaurant, serves breakfast, lunch, and dinner, and Ban.ter Treehouse, the 13th-floor rooftop bar and restaurant serves small plates and cocktails. The indoor/outdoor flow of the latter rooftop restaurant is lush with lots of plants and palm trees and seating is a mix of bartop and four-person tables spread around a sparkling infinity pool. On weekends, a poolside DJ plays high-energy music. COVID-19 procedures are available here. Kimpton Angler's South Beach The hotel is just two blocks from the beach. Tripadvisor Book Kimpton Angler's South BeachCategory: Boutique Town: South Beach, Miami Typical starting/peak prices: $228/$483Best for: Couples, families, IHG Kimpton reward members, travelers with pets   On-site amenities: Evening wine hours, complimentary morning coffee, Orange Theory fitness classes, in-room spa treatments, pool, restaurant, bar, beach accessPros: The Kimpton Angler is just two blocks from the beach and accommodations are large, with options for two and three-story lofts and bungalows.Cons: There's no fitness center, but the hotel has a partnership with OrangeTheory fitness, and classes are included in your stay. Also, there's a charge for Wi-Fi if you're not an IHG Kimpton rewards member.Kimpton hotels are known for their well-designed boutique properties, the Kimpton Angler's South Beach is no exception. Located on the south end of Miami Beach, it's also minutes from the nightlife on Ocean DriveThere's a cohesive nautical theme carried throughout, with sand-colored loveseats, wicker lamps, and navy patterned lounge chairs and curtains in the 132 guest rooms and suites. Standard rooms are 400 square feet with King or Queen sized beds, ample closet space, and oversized walk-in showers with separate tubs. Most rooms also have balconies that overlook either Washington Ave or the hotel's courtyard Mermaid Pool. The sixth-floor rooftop pool and sun deck is a standout feature, with chic black and white lounge chairs framed by panoramic views of the Miami skyline. Large potted plants add privacy to lounge areas, and the pool deck is quiet enough for those who want to catch up on reading. After a dip, order drinks like the photogenic watermelon margarita from the Minnow Bar. COVID-19 procedures are available here. Conrad Miami The sleek pool terrace is one of multiple rooftop lounge areas at the Conrad Miami. Tripadvisor Book Conrad MiamiCategory: LuxuryTown: Brickell, MiamiTypical starting/peak prices: $275/$574Best for: Couples, Hilton loyalists   On-site amenities: Spa, hot tub, rooftop tennis courts, restaurant, pool, barPros: In addition to the great views, the hotel is in a walkable neighborhood and the customer service is top-notch. Cons: Part of the hotel is commercial real estate, and floors 4-15 are business offices, which may take away from the luxury hotel feel. Also, the lobby is located on the 25th floor, which can be confusing.Conrad Miami is in the heart of Brickell, Miami's business district near upscale, art, and dining. This hotel has multiple great outdoor spaces, but chief among them is Nativo Kitchen and Bar on the 25th floor with views of Virginia Key Beach, Key Biscayne, and Biscayne Bay.There is also the 13th-floor rooftop pool with sleek cabanas and the adjacent Sky Pool Bar, serving a casual menu of burgers and chicken wings, local and imported beers, and frozen cocktails.  When not sunning yourself on one of these terraces, retreat to guest rooms with a clean, minimalist style and light wood furniture, gold fixtures, and baby blue accent chairs. Standard rooms have a separate bathtub and shower, complimentary bathrobes, and 50-inch televisions, and all rooms come with wide windows that offer city or ocean views.COVID-19 procedures are available here. The Dalmar, Tribute Portfolio A saltwater pool is flanked by a sleek bar. Tripadvisor Book The Dalmar, Tribute PortfolioCategory: Luxury Town: Fort Lauderdale Typical starting/peak prices: $284/$455 Best for: FriendsOn-site amenities: Yoga classes, restaurants, pool, bar, coffee shopPros: The rooftop restaurant, Sparrow, is great for adults-only celebrations and has exceptional views of Fort Lauderdale. Cons: Past guests have noted that food and drink prices are steep. The Dalmar is located in downtown Fort Lauderdale, only two miles from Fort Lauderdale beach. From framed art by the Lobby Bar restaurant to the living plant wall adorning Rose's Coffee shop near the hotel's entrance, fun design features prominently.There are two great rooftop venues on the 6th floor of the hotel. Sparrow is an indoor/outdoor restaurant and bar, and after 9 p.m., the venue turns into a 21+ lounge. There's a strict dress code (no athletic gear or beachwear) and a DJ that spins late into the night.The other rooftop venue is the saltwater pool reserved for hotel guests, but the poolside bar and grill, Sip and Dip, is open to everyone from 10 a.m. to 6 p.m.Inside, guest rooms have midcentury flair with pastel furniture, pleated curtains, and brass lamps. The rooms also have premium Sferra sheets, spacious bathrooms with rainfall showers, and tablets for ordering in-room services. Most rooms have floor-to-ceiling views of either Fort Lauderdale or the Intracoastal and select rooms have balconies. COVID-19 procedures are available here. The Ben, Autograph Collection Spruzzo serves coastal Italian cuisine on the rooftop. Tripadvisor Book The Ben, Autograph CollectionCategory: Luxury Town: West Palm Beach Typical starting/peak prices: $286/$483Best for: Couples, Marriott loyalists, travelers with pets  On-site amenities: Rooftop fire pit, hotel library, in-room dining, pet-friendly rooms, restaurant, poolPros: In addition to the great downtown location and views of the waterfront, Spruzzo, the hotel's Italian rooftop restaurant, has a delicious menu and extensive imported wines. Cons: Spruzzo doesn't take reservations, but instead operates on a first-come, first-served policy. One of the newest additions to downtown West Palm Beach is the waterfront hotel, The Ben. The Marriott-owned luxury boutique hotel commands a great location within walking distance of Clematis Street, West Palm Beach's lively district filled with restaurants and bars, and Rosemary Square, an upscale shopping and dining destination. Guest rooms are polished, with sleek wood floors, leather pleated headboards, and luxe Turkish linens. A standard Interior Double Queen is a comfortable 343 square feet, and many guest rooms have views of Palm Harbor Marina or Palm Beach Island. The hotel's 7th-floor rooftop restaurant and bar, Spruzzo, is quite popular, especially on weekends, serving coastal Italian cuisine. It's quickly become a local hangout for young professionals. During the day, hotel guests may reserve one of the cabanas next to the heated saltwater pool, and at night, enjoy watching the sunset over the Palm Beach Intracoastal from the fire pit with a cocktail in hand. COVID-19 procedures are available here. Moxy Miami South Beach There are six different hotel restaurants including a swanky rooftop lounge. Marriott Book Moxy Miami South BeachCategory: BoutiqueTown: South Beach, MiamiTypical starting/peak prices: $289/$489Best for: Friends, Marriott loyalists Onsite amenities: 6 dining and drinking venues, pet-friendly rooms, complimentary beach chairs, complimentary rooftop fitness classes, complimentary morning coffee, poolPros: The Upside rooftop level has incredible views of the South Beach oceanfront along with plenty of seating. Each guestroom also have two beach chairs on South Beach included. Cons: Although there's plenty of places to sunbathe, The Upside rooftop only has a shallow wading pool.Newly opened Moxy Miami South Beach is the first resort-style property for the Moxy brand.Only two blocks from the bustling nightlife of South Beach, the hotel gets lively, especially on the weekends and caters to a young crowd. The purposeful design features lots of Instagrammable details like neon wall signs and fun pool floats.Standard guestrooms are a cozy 224 square feet but maximize the space with retro details like rotary phones and custom artwork by local Miami artists. Walk-in rain showers and Egyptian cotton linens add a sumptuous touch.There are six different hotel restaurants including a lobby bar, Bar Moxy, and Serena, an elevated Mexican restaurant in a lush garden setting adjacent to the hotel's main 72-foot pool. The hotel's 8th story rooftop, The Upside is reserved for hotel guests and has a shallow pool, lounge chairs, and plenty of daybeds. The Upside has great views of South Beach, and a DJ spins house and hip-hop tunes throughout the afternoon and evening. The hotel also offers complimentary bikes (helmets included) to explore the neighborhood. COVID-19 procedures are available here. The Betsy South Beach The oceanfront deck offers a front-row view of the Atlantic Ocean. Tripadvisor Book The Betsy South BeachCategory: BoutiqueTown: South Beach, MiamiTypical starting/peak prices: $289/$609Best for: Couples, travelers with pets On-site amenities: Spa, library, fitness center, restaurants, bars, arts and cultural programming, beach access, poolPros: With only 130 rooms, the hotel offers a peaceful, intimate South Beach stay and all the arts programming is a boon for culture enthusiasts. Cons: Restaurant menu items are expensive and come with an automatic 20% gratuity fee, but that's on par with most hotels on Ocean Drive.The Betsy Hotel is a landmark hotel on South Beach located on Miami's main strip, Ocean Drive, but is tucked away from the noise of the nightclubs and late-night revelry. Arts programming features heavily here, drawing a sophisticated crowd of well-heeled creative types who book posh, albeit sometimes small, rooms with walnut floors, velvet armchairs, and cream-colored curtains that frame floor-to-ceiling windows. The 250-square-foot standard Classic King is cozy but comes with a marble bathroom, a large walk-in shower, luxe Sferra linens, and is pet-friendly, welcoming dogs under 40 pounds. There are two pools: a courtyard pool and a fourth-floor rooftop infinity pool with chaise lounges and 360-degree views of Miami. The bar serves poolside drinks, and food may be brought up from the hotel's restaurant, LT Steak & Seafood. After a swim, catch a sunset from the rooftop's Skyline Deck, a patio overlooking the ocean with unobstructed water views.COVID-19 procedures are available here. East Miami An expansive rooftop pool deck has stellar views over the city and multiple areas to swim. Tripadvisor Book East MiamiCategory: Luxury Town: Brickell, MiamiTypical starting/peak prices: $305/$529Best for: Couples, business travelersOn-site amenities: 24-hour fitness center with classes, complimentary bicycles, restaurants, 4 pools, barsPros: Sugar, the bar on the 40th floor, has one of the best views of downtown Miami and some of the best cocktails I've had in Miami. Cons: The food and cocktails at Sugar are great, but even with a reservation, the wait is long and service can be slow. East Miami is centrally located in downtown Brickell and Sugar, the hotel's rooftop restaurant and bar on the 40th floor has arguably the best view of the entire Miami skyline.The restaurant is 21+ after 6 p.m. and there's a strict dress code (nightlife attire is enforced after sunset). Equally impressive are the four pools (a lap pool, spa pool, plunge pool, and hot tub) on the hotel's fifth-floor deck. So many offerings mean you won't have to worry about waiting for a sun lounger.Standard guest rooms start at 300 square feet, though there are also has large one, two, and three-bedroom residences. All 352 rooms come with a private balcony, floor-to-ceiling windows, and contemporary decor that includes cream-colored furniture, teal wallpaper, and orange throw pillows. COVID-19 procedures are available here. 1 Hotel South Beach Four distinct pool decks offer incredible views. 1 Hotel South Beach/TripAdvisor Book 1 Hotel South BeachCategory: Luxury Town: South Beach, MiamiTypical starting/peak prices: $425/$899Best for: Couples, friends, familiesOn-site amenities: Spa, fitness classes, salon, pet-friendly rooms, coffee and juice bar, beach club, restaurants, bars, multiple poolsPros: There are four different dazzling pool areas, one of which has stunning views from the hotel's 18th-story rooftop. Food, rooms, and customer service are all outstanding at this hotel. Cons: Prices can more than double during the winter high season, and the hotel's 18 story rooftop pool is restricted to adults 21+.Considered one of the best hotels on South Beach, 1 Hotel South Beach takes up an entire block and sits on 600 feet of Miami's prime beachfront. The hotel is pricey but worth the splurge for its sophisticated boho beach vibes, impeccable service, outstanding food, and airy rooms.The lobby makes a remarkable first impression with soaring ceilings and crisp seating around glass-topped wooden coffee tables, but it's the multiple pool decks that really dazzle.There are four different pools: the beachfront South pool, the third floor Cabana Pool, the enormous 30,000 square foot Center Pool, and the gorgeous 18th-story rooftop pool, Watr at the 1 Hotel Rooftop, which is Miami's largest rooftop pool and lounge. Inside, the 426 guest rooms are a celebration of nature and sustainability, sourcing most items from reclaimed materials. A coastal-inspired color palette and large windows make them feel airy and light alongside beachy accents featuring driftwood, tree stumps, and custom wood plank headboards. COVID-19 procedures are available here. FAQ: South Florida hotels When is the best time to visit South Florida?While South Florida experiences nearly year-round sunshine, the best time to visit is from February to May. During those months, temperatures are cooler, and crowds tend to taper off, although there is a spike of visitors during spring break.During the summer months, the temperature and humidity soar, and daily afternoon thunderstorms are common. Florida's hurricane season starts June 1 and lasts until the end of November with August and September being the most active hurricane months.Weather-wise, November through January is also a good time to visit. The temperatures hover around 75 degrees, although it's not uncommon to experience a few sub 50 degree days when a cold front comes through. But keep in mind that hotel prices tend to peak during the November to January holiday months. Do I have to book a room to visit a hotel rooftop?Many of the hotels included in this list have rooftop bars and restaurants open to the public that do not require an overnight hotel reservation, but most of the rooftop pools are reserved for hotel guests. Some hotels offer daytime cabana rentals or a day pass through Resort Pass that includes access to the hotel's pool, spa, or other amenities. Availability changes often, so always call ahead and ask. How do I get around South Florida?South Florida is a large area that encompasses three counties: Broward, Miami-Dade, and Monroe, though most locals consider southern cities in Palm Beach County like West Palm Beach as part of South Florida.Touring South Florida requires a car and some planning as traffic can get congested, especially during morning and evening rush hours. While the public transportation system is mostly reliable in downtown areas, renting a car is the best way to explore all of South Florida. If you're flying into Miami, Fort Lauderdale, or West Palm Beach and staying close to your hotel, you can use taxis or rideshare apps to get around. How do I find a hotel with a rooftop?Most hotels with a rooftop will list it on their hotel website, and third-party booking sites like Booking.com and Hotels.com will usually include a  rooftop in the hotel description or on the list of hotel amenities. Also, the third-party booking site Kayak has a search filter to only pull up properties with rooftops. Do hotel guests receive priority on rooftops?It depends on the property. Most of the hotels restrict the pool areas to hotel guests or guests with day passes. Rooftops with a combined pool and restaurant area do take outside reservations, so it's advised to make restaurant reservations when checking in. How we selected the best South Florida hotels with rooftops I'm a South Florida-based travel writer and have personally visited almost every hotel on this list. All of the hotel rooftops have an excellent bar or restaurant, a picturesque pool, and sensational city or ocean views.Every hotel is located in a popular neighborhood in West Palm Beach, Fort Lauderdale, or Miami. Some of the hotels have downtown locations close to shopping, museums, and restaurants. Others are beachfront or within walking distance to the beach.Besides the great rooftops, many of the properties include perks like a nightly hosted wine hour, complimentary bicycles, and pet-friendly guest rooms.All of the properties have excellent recent reviews on third-party travel sites like Tripadvisor or Booking.com.Because of the location and amenities of the properties, most of the hotels are in the luxury category, but booking during low season can lock in reasonable rates.We've indicated which hotels are ideal for couples, friends, families, or solo travelers, and have included a mix of all kinds of properties.Each hotel promotes COVID safe practices and has updated its COVID practices to include enhanced cleaning procedures. More of the best hotels in Florida Trip Advisor The best hotels in FloridaThe best beach hotels in FloridaThe best hotels in South BeachThe best hotels in MiamiThe best hotels in Key WestThe best hotels in Fort LauderdaleThe best hotels in Orlando and KissimmeeThe best hotels in Walt Disney WorldThe best hotels in Destin Read the original article on Business Insider.....»»

Category: topSource: businessinsiderSep 23rd, 2021